{"title":"GLP-1","description":"","products":[{"product_id":"bioglutide","title":"Bioglutide 100x100mg","description":"\u003cp data-start=\"0\" data-end=\"404\"\u003e                                           \u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eNOT FOR HUMAN CONSUMPTION\u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-start=\"0\" data-end=\"404\"\u003e\u003cstrong data-start=\"0\" data-end=\"51\"\u003eBioglutide (NA-931) \u003c\/strong\u003e is positioned as a \u003cstrong data-start=\"465\" data-end=\"484\"\u003eonce-daily pill\u003c\/strong\u003e aiming to combine \u003cstrong data-start=\"503\" data-end=\"541\"\u003eincretin satiety\/glycaemic control\u003c\/strong\u003e (GLP-1, GIP), \u003cstrong data-start=\"556\" data-end=\"596\"\u003eenergy-expenditure and hepatic lipid\u003c\/strong\u003e effects (glucagon), and \u003cstrong data-start=\"621\" data-end=\"652\"\u003eanabolism\/lean-mass support\u003c\/strong\u003e (claimed IGF-1 receptor activity). If verified, the mix would theoretically pair \u003cstrong data-start=\"734\" data-end=\"763\"\u003edeep appetite suppression\u003c\/strong\u003e with \u003cstrong data-start=\"769\" data-end=\"798\"\u003ehigher energy expenditure\u003c\/strong\u003e and \u003cstrong data-start=\"803\" data-end=\"838\"\u003ebetter body-composition quality\u003c\/strong\u003e than GLP-1 monotherapy. Evidence confirming \u003cstrong data-start=\"883\" data-end=\"936\"\u003edirect IGF-1 receptor agonism by a small molecule\u003c\/strong\u003e is sparse in the literature, so this aspect should be viewed as \u003cstrong data-start=\"1001\" data-end=\"1013\"\u003eunproven\u003c\/strong\u003e pending peer-review. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"1074\" data-end=\"1077\"\u003e\n\u003ch3 data-start=\"1079\" data-end=\"1140\"\u003eAdditional Benefits of Bioglutide Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"1142\" data-end=\"3350\" class=\"w-fit min-w-(--thread-content-width)\" style=\"width: 100%; height: 569px;\"\u003e\n\u003cthead data-start=\"1142\" data-end=\"1170\"\u003e\n\u003ctr data-start=\"1142\" data-end=\"1170\" style=\"height: 19px;\"\u003e\n\u003cth data-start=\"1142\" data-end=\"1152\" data-col-size=\"sm\" style=\"width: 19.788043%; height: 19px;\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-start=\"1152\" data-end=\"1170\" data-col-size=\"xl\" style=\"width: 77.429348%; height: 19px;\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"1181\" data-end=\"3350\"\u003e\n\u003ctr data-start=\"1181\" data-end=\"1466\" style=\"height: 75px;\"\u003e\n\u003ctd data-start=\"1181\" data-end=\"1221\" data-col-size=\"sm\" style=\"width: 19.788043%; height: 75px;\"\u003e\u003cstrong data-start=\"1183\" data-end=\"1220\"\u003e1 Oral, multi-pathway weight loss\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1221\" data-end=\"1466\" data-col-size=\"xl\" style=\"width: 77.429348%; height: 75px;\"\u003eCompany-reported Phase 2 data (13 weeks) cite \u003cstrong data-start=\"1269\" data-end=\"1302\"\u003edouble-digit mean weight loss\u003c\/strong\u003e at higher doses, with \u003cstrong data-start=\"1325\" data-end=\"1361\"\u003eplacebo-adjusted reductions \u0026gt;10%\u003c\/strong\u003e in top arms. Independent, peer-reviewed confirmation is pending. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1467\" data-end=\"1691\" style=\"height: 57px;\"\u003e\n\u003ctd data-start=\"1467\" data-end=\"1500\" data-col-size=\"sm\" style=\"width: 19.788043%; height: 57px;\"\u003e\u003cstrong data-start=\"1469\" data-end=\"1499\"\u003e2 Glycaemic control in T2D\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1500\" data-end=\"1691\" data-col-size=\"xl\" style=\"width: 77.429348%; height: 57px;\"\u003eAims to deliver \u003cstrong data-start=\"1518\" data-end=\"1536\"\u003eA1c reductions\u003c\/strong\u003e comparable to injectable incretins while being oral; formal peer-reviewed T2D results have not yet been published. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1692\" data-end=\"2008\" style=\"height: 76px;\"\u003e\n\u003ctd data-start=\"1692\" data-end=\"1732\" data-col-size=\"sm\" style=\"width: 19.788043%; height: 76px;\"\u003e\u003cstrong data-start=\"1694\" data-end=\"1731\"\u003e3 Energy-expenditure boost (GCGR)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1732\" data-end=\"2008\" data-col-size=\"xl\" style=\"width: 77.429348%; height: 76px;\"\u003eGlucagon receptor engagement is expected to \u003cstrong data-start=\"1778\" data-end=\"1814\"\u003eraise resting energy expenditure\u003c\/strong\u003e and \u003cstrong data-start=\"1819\" data-end=\"1844\"\u003epromote fat oxidation\u003c\/strong\u003e, potentially countering metabolic adaptation seen with weight loss. Human EE data for NA-931 have not been publicly vetted. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2009\" data-end=\"2252\" style=\"height: 57px;\"\u003e\n\u003ctd data-start=\"2009\" data-end=\"2051\" data-col-size=\"sm\" style=\"width: 19.788043%; height: 57px;\"\u003e\u003cstrong data-start=\"2011\" data-end=\"2050\"\u003e4 Lean-mass preservation (IGF-axis)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2051\" data-end=\"2252\" data-col-size=\"xl\" style=\"width: 77.429348%; height: 57px;\"\u003eBy adding an IGF-1 component, NA-931 is pitched to \u003cstrong data-start=\"2104\" data-end=\"2123\"\u003epreserve muscle\u003c\/strong\u003e during weight loss; \u003cstrong data-start=\"2144\" data-end=\"2163\"\u003edirect evidence\u003c\/strong\u003e in humans has not been disclosed in peer-review. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2253\" data-end=\"2512\" style=\"height: 57px;\"\u003e\n\u003ctd data-start=\"2253\" data-end=\"2286\" data-col-size=\"sm\" style=\"width: 19.788043%; height: 57px;\"\u003e\u003cstrong data-start=\"2255\" data-end=\"2285\"\u003e5 Liver fat \u0026amp; MASH signals\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2286\" data-end=\"2512\" data-col-size=\"xl\" style=\"width: 77.429348%; height: 57px;\"\u003eA quadruple profile could reduce \u003cstrong data-start=\"2321\" data-end=\"2333\"\u003eMRI-PDFF\u003c\/strong\u003e and improve \u003cstrong data-start=\"2346\" data-end=\"2357\"\u003eALT\/AST\u003c\/strong\u003e (weight loss + glucagon hepatolipid effects); trials in metabolic liver disease are referenced as ongoing\/planned. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2513\" data-end=\"2711\" style=\"height: 57px;\"\u003e\n\u003ctd data-start=\"2513\" data-end=\"2545\" data-col-size=\"sm\" style=\"width: 19.788043%; height: 57px;\"\u003e\u003cstrong data-start=\"2515\" data-end=\"2544\"\u003e6 Convenience \u0026amp; adherence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2545\" data-end=\"2711\" data-col-size=\"xl\" style=\"width: 77.429348%; height: 57px;\"\u003e\n\u003cstrong data-start=\"2547\" data-end=\"2555\"\u003eOral\u003c\/strong\u003e dosing may improve \u003cstrong data-start=\"2575\" data-end=\"2601\"\u003euptake and persistence\u003c\/strong\u003e vs injectables for some patients, assuming tolerability is favorable. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2712\" data-end=\"2946\" style=\"height: 57px;\"\u003e\n\u003ctd data-start=\"2712\" data-end=\"2742\" data-col-size=\"sm\" style=\"width: 19.788043%; height: 57px;\"\u003e\u003cstrong data-start=\"2714\" data-end=\"2741\"\u003e7 Combination potential\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2742\" data-end=\"2946\" data-col-size=\"xl\" style=\"width: 77.429348%; height: 57px;\"\u003eCompany materials suggest \u003cstrong data-start=\"2770\" data-end=\"2780\"\u003eadd-on\u003c\/strong\u003e use with GLP-1\/GIP injectables (e.g., semaglutide\/tirzepatide) for extra weight loss; this is \u003cstrong data-start=\"2875\" data-end=\"2900\"\u003ehypothesis-generating\u003c\/strong\u003e only. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2947\" data-end=\"3173\" style=\"height: 57px;\"\u003e\n\u003ctd data-start=\"2947\" data-end=\"2984\" data-col-size=\"sm\" style=\"width: 19.788043%; height: 57px;\"\u003e\u003cstrong data-start=\"2949\" data-end=\"2983\"\u003e8 Cardiometabolic risk factors\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2984\" data-end=\"3173\" data-col-size=\"xl\" style=\"width: 77.429348%; height: 57px;\"\u003eExpectation (by mechanism\/class): \u003cstrong data-start=\"3020\" data-end=\"3043\"\u003eBP and triglyceride\u003c\/strong\u003e reductions, \u003cstrong data-start=\"3056\" data-end=\"3072\"\u003enon-HDL\/apoB\u003c\/strong\u003e improvements; formal datasets for NA-931 are not yet public. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3174\" data-end=\"3350\" style=\"height: 57px;\"\u003e\n\u003ctd data-start=\"3174\" data-end=\"3208\" data-col-size=\"sm\" style=\"width: 19.788043%; height: 57px;\"\u003e\u003cstrong data-start=\"3176\" data-end=\"3207\"\u003e9 Patient-reported outcomes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3208\" data-end=\"3350\" data-col-size=\"xl\" style=\"width: 77.429348%; height: 57px;\"\u003eAnticipated gains in \u003cstrong data-start=\"3231\" data-end=\"3271\"\u003esatiety, cravings, physical function\u003c\/strong\u003e—data not yet peer-reviewed for NA-931. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"3352\" data-end=\"3355\"\u003e\n\u003ch2 data-start=\"3357\" data-end=\"3392\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-start=\"3394\" data-end=\"3437\"\u003e2.1 Receptor pharmacodynamics (claimed)\u003c\/h3\u003e\n\u003cul data-start=\"3438\" data-end=\"4101\"\u003e\n\u003cli data-start=\"3438\" data-end=\"3542\"\u003e\n\u003cp data-start=\"3440\" data-end=\"3542\"\u003e\u003cstrong data-start=\"3440\" data-end=\"3451\"\u003eGLP-1R:\u003c\/strong\u003e ↓ appetite, ↓ gastric emptying; glucose-dependent \u003cstrong data-start=\"3502\" data-end=\"3514\"\u003einsulin↑\u003c\/strong\u003e, \u003cstrong data-start=\"3516\" data-end=\"3529\"\u003eglucagon↓\u003c\/strong\u003e post-meal.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3543\" data-end=\"3671\"\u003e\n\u003cp data-start=\"3545\" data-end=\"3671\"\u003e\u003cstrong data-start=\"3545\" data-end=\"3554\"\u003eGIPR:\u003c\/strong\u003e Potentiates insulin secretion; may improve \u003cstrong data-start=\"3598\" data-end=\"3633\"\u003eadipocyte metabolic flexibility\u003c\/strong\u003e and \u003cstrong data-start=\"3638\" data-end=\"3657\"\u003eGI tolerability\u003c\/strong\u003e with GLP-1.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3672\" data-end=\"3804\"\u003e\n\u003cp data-start=\"3674\" data-end=\"3804\"\u003e\u003cstrong data-start=\"3674\" data-end=\"3694\"\u003eGCGR (glucagon):\u003c\/strong\u003e \u003cstrong data-start=\"3695\" data-end=\"3719\"\u003e↑ energy expenditure\u003c\/strong\u003e and fat oxidation; mobilizes hepatic lipid with careful glycaemic counter-balance.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3805\" data-end=\"4101\"\u003e\n\u003cp data-start=\"3807\" data-end=\"4101\"\u003e\u003cstrong data-start=\"3807\" data-end=\"3828\"\u003eIGF-1R (claimed):\u003c\/strong\u003e \u003cstrong data-start=\"3829\" data-end=\"3856\"\u003eAnabolic\/anti-catabolic\u003c\/strong\u003e signaling (Akt–mTOR); preservation of \u003cstrong data-start=\"3895\" data-end=\"3908\"\u003elean mass\u003c\/strong\u003e. \u003cem data-start=\"3910\" data-end=\"3917\"\u003eNote:\u003c\/em\u003e \u003cstrong data-start=\"3918\" data-end=\"3969\"\u003eDirect, selective small-molecule IGF-1R agonism\u003c\/strong\u003e is biologically unusual and currently \u003cstrong data-start=\"4008\" data-end=\"4022\"\u003eunverified\u003c\/strong\u003e for NA-931 outside company statements. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"4103\" data-end=\"4130\"\u003e2.2 Down-stream biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"4132\" data-end=\"4507\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"4132\" data-end=\"4174\"\u003e\n\u003ctr data-start=\"4132\" data-end=\"4174\"\u003e\n\u003cth data-start=\"4132\" data-end=\"4142\" data-col-size=\"sm\"\u003ePathway\u003c\/th\u003e\n\u003cth data-start=\"4142\" data-end=\"4163\" data-col-size=\"sm\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-start=\"4163\" data-end=\"4174\" data-col-size=\"sm\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"4189\" data-end=\"4507\"\u003e\n\u003ctr data-start=\"4189\" data-end=\"4256\"\u003e\n\u003ctd data-start=\"4189\" data-end=\"4211\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"4191\" data-end=\"4210\"\u003ePOMC\/AgRP (CNS)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"4211\" data-end=\"4235\" data-col-size=\"sm\"\u003eSatiety ↑, cravings ↓\u003c\/td\u003e\n\u003ctd data-start=\"4235\" data-end=\"4256\" data-col-size=\"sm\"\u003eAppetite circuits\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"4257\" data-end=\"4330\"\u003e\n\u003ctd data-start=\"4257\" data-end=\"4288\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"4259\" data-end=\"4287\"\u003eIslet incretin signaling\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"4288\" data-end=\"4318\" data-col-size=\"sm\"\u003eGlucose-dependent insulin ↑\u003c\/td\u003e\n\u003ctd data-start=\"4318\" data-end=\"4330\" data-col-size=\"sm\"\u003ePancreas\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"4331\" data-end=\"4407\"\u003e\n\u003ctd data-start=\"4331\" data-end=\"4367\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"4333\" data-end=\"4366\"\u003eHepatic lipid handling (GCGR)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"4367\" data-end=\"4398\" data-col-size=\"sm\"\u003eFat oxidation ↑, steatosis ↓\u003c\/td\u003e\n\u003ctd data-start=\"4398\" data-end=\"4407\" data-col-size=\"sm\"\u003eLiver\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"4408\" data-end=\"4507\"\u003e\n\u003ctd data-start=\"4408\" data-end=\"4434\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"4410\" data-end=\"4433\"\u003eAkt–mTOR (IGF-axis)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"4434\" data-end=\"4472\" data-col-size=\"sm\"\u003eProtein synthesis\/lean mass support\u003c\/td\u003e\n\u003ctd data-start=\"4472\" data-end=\"4507\" data-col-size=\"sm\"\u003eMuscle (theoretical for NA-931)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"4509\" data-end=\"4512\"\u003e\n\u003ch2 data-start=\"4514\" data-end=\"4536\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cul data-start=\"4538\" data-end=\"4876\"\u003e\n\u003cli data-start=\"4538\" data-end=\"4611\"\u003e\n\u003cp data-start=\"4540\" data-end=\"4611\"\u003e\u003cstrong data-start=\"4540\" data-end=\"4562\"\u003eFormulation\/Route:\u003c\/strong\u003e \u003cstrong data-start=\"4563\" data-end=\"4578\"\u003eOral tablet\u003c\/strong\u003e, once daily (company reports).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4612\" data-end=\"4728\"\u003e\n\u003cp data-start=\"4614\" data-end=\"4728\"\u003e\u003cstrong data-start=\"4614\" data-end=\"4637\"\u003eHalf-life\/Exposure:\u003c\/strong\u003e Not published in peer-review; dose-ranging has been presented in company communications.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4729\" data-end=\"4785\"\u003e\n\u003cp data-start=\"4731\" data-end=\"4785\"\u003e\u003cstrong data-start=\"4731\" data-end=\"4758\"\u003eFood effect\/Absorption:\u003c\/strong\u003e Not disclosed in detail.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4786\" data-end=\"4876\"\u003e\n\u003cp data-start=\"4788\" data-end=\"4876\"\u003e\u003cstrong data-start=\"4788\" data-end=\"4802\"\u003eDrug–drug:\u003c\/strong\u003e No public interaction matrix yet. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"4878\" data-end=\"4881\"\u003e\n\u003ch2 data-start=\"4883\" data-end=\"4937\"\u003e4. Pre-clinical \u0026amp; Clinical Evidence (what’s public)\u003c\/h2\u003e\n\u003cul data-start=\"4939\" data-end=\"5433\"\u003e\n\u003cli data-start=\"4939\" data-end=\"5228\"\u003e\n\u003cp data-start=\"4941\" data-end=\"5228\"\u003e\u003cstrong data-start=\"4941\" data-end=\"4980\"\u003ePhase 2 obesity (company-reported):\u003c\/strong\u003e ~\u003cstrong data-start=\"4982\" data-end=\"4993\"\u003e13-week\u003c\/strong\u003e study with \u003cstrong data-start=\"5005\" data-end=\"5035\"\u003edose-dependent weight loss\u003c\/strong\u003e; a high-dose arm reportedly \u003cstrong data-start=\"5064\" data-end=\"5103\"\u003e~14–15% total body-weight reduction\u003c\/strong\u003e and \u003cstrong data-start=\"5108\" data-end=\"5133\"\u003e~13% placebo-adjusted\u003c\/strong\u003e—awaiting peer-review and full protocol transparency. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5229\" data-end=\"5433\"\u003e\n\u003cp data-start=\"5231\" data-end=\"5433\"\u003e\u003cstrong data-start=\"5231\" data-end=\"5254\"\u003eDevelopment status:\u003c\/strong\u003e Communicated as moving toward \u003cstrong data-start=\"5285\" data-end=\"5299\"\u003ePhase 2b\/3\u003c\/strong\u003e in \u003cstrong data-start=\"5303\" data-end=\"5318\"\u003eobesity\/T2D\u003c\/strong\u003e; registry and pipeline round-ups list NA-931 in \u003cstrong data-start=\"5367\" data-end=\"5380\"\u003emid-stage\u003c\/strong\u003e development. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cblockquote data-start=\"5435\" data-end=\"5687\"\u003e\n\u003cp data-start=\"5437\" data-end=\"5687\"\u003e\u003cstrong data-start=\"5437\" data-end=\"5463\"\u003eEvidence quality note:\u003c\/strong\u003e To date, \u003cstrong data-start=\"5473\" data-end=\"5499\"\u003enearly all information\u003c\/strong\u003e comes from \u003cstrong data-start=\"5511\" data-end=\"5537\"\u003ecompany press releases\u003c\/strong\u003e, \u003cstrong data-start=\"5539\" data-end=\"5566\"\u003eindustry trade coverage\u003c\/strong\u003e, or \u003cstrong data-start=\"5571\" data-end=\"5593\"\u003epipeline summaries\u003c\/strong\u003e—not peer-reviewed journals. Treat efficacy magnitudes and receptor claims as \u003cstrong data-start=\"5671\" data-end=\"5686\"\u003epreliminary\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003chr data-start=\"5689\" data-end=\"5692\"\u003e\n\u003ch2 data-start=\"5694\" data-end=\"5727\"\u003e5. Emerging Clinical Interests\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"5729\" data-end=\"6163\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"5729\" data-end=\"5759\"\u003e\n\u003ctr data-start=\"5729\" data-end=\"5759\"\u003e\n\u003cth data-start=\"5729\" data-end=\"5737\" data-col-size=\"sm\"\u003eField\u003c\/th\u003e\n\u003cth data-start=\"5737\" data-end=\"5749\" data-col-size=\"md\"\u003eRationale\u003c\/th\u003e\n\u003cth data-start=\"5749\" data-end=\"5759\" data-col-size=\"sm\"\u003eStatus\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"5774\" data-end=\"6163\"\u003e\n\u003ctr data-start=\"5774\" data-end=\"5878\"\u003e\n\u003ctd data-start=\"5774\" data-end=\"5806\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5776\" data-end=\"5805\"\u003eChronic weight management\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5806\" data-end=\"5852\" data-col-size=\"md\"\u003eOral option with multi-hormone pharmacology\u003c\/td\u003e\n\u003ctd data-start=\"5852\" data-end=\"5878\" data-col-size=\"sm\"\u003ePhase 2→2b\/3 (company)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5879\" data-end=\"5981\"\u003e\n\u003ctd data-start=\"5879\" data-end=\"5901\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5881\" data-end=\"5900\"\u003eType 2 diabetes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5901\" data-end=\"5950\" data-col-size=\"md\"\u003eA1c + weight + potential metabolic flexibility\u003c\/td\u003e\n\u003ctd data-start=\"5950\" data-end=\"5981\" data-col-size=\"sm\"\u003ePlanned\/ongoing per company\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5982\" data-end=\"6063\"\u003e\n\u003ctd data-start=\"5982\" data-end=\"5999\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5984\" data-end=\"5998\"\u003eMASH\/NAFLD\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5999\" data-end=\"6048\" data-col-size=\"md\"\u003eWeight + glucagon-driven hepatic lipid effects\u003c\/td\u003e\n\u003ctd data-start=\"6048\" data-end=\"6063\" data-col-size=\"sm\"\u003eExploratory\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6064\" data-end=\"6163\"\u003e\n\u003ctd data-start=\"6064\" data-end=\"6099\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6066\" data-end=\"6098\"\u003eCombination with injectables\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6099\" data-end=\"6133\" data-col-size=\"md\"\u003eAdditive weight loss hypothesis\u003c\/td\u003e\n\u003ctd data-start=\"6133\" data-end=\"6163\" data-col-size=\"sm\"\u003ePreclinical\/company claims\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"6165\" data-end=\"6168\"\u003e\n\u003ch2 data-start=\"6170\" data-end=\"6236\"\u003e6. Safety and Tolerability (what to expect, what we don’t know)\u003c\/h2\u003e\n\u003cul data-start=\"6238\" data-end=\"7065\"\u003e\n\u003cli data-start=\"6238\" data-end=\"6379\"\u003e\n\u003cp data-start=\"6240\" data-end=\"6379\"\u003e\u003cstrong data-start=\"6240\" data-end=\"6284\"\u003eLikely class AEs (if incretin-dominant):\u003c\/strong\u003e \u003cstrong data-start=\"6285\" data-end=\"6328\"\u003eNausea, vomiting, diarrhea\/constipation\u003c\/strong\u003e, abdominal pain (generally titration-dependent).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6380\" data-end=\"6509\"\u003e\n\u003cp data-start=\"6382\" data-end=\"6509\"\u003e\u003cstrong data-start=\"6382\" data-end=\"6405\"\u003eGlucagon component:\u003c\/strong\u003e Possible \u003cstrong data-start=\"6415\" data-end=\"6431\"\u003e↑ heart rate\u003c\/strong\u003e, \u003cstrong data-start=\"6433\" data-end=\"6463\"\u003eglycaemic counter-pressure\u003c\/strong\u003e (balanced by GLP-1\/GIP); monitor \u003cstrong data-start=\"6497\" data-end=\"6506\"\u003eBP\/HR\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6510\" data-end=\"6702\"\u003e\n\u003cp data-start=\"6512\" data-end=\"6702\"\u003e\u003cstrong data-start=\"6512\" data-end=\"6548\"\u003eIGF-axis concerns (theoretical):\u003c\/strong\u003e If genuine IGF-1R agonism occurs, watch \u003cstrong data-start=\"6589\" data-end=\"6598\"\u003eedema\u003c\/strong\u003e, \u003cstrong data-start=\"6600\" data-end=\"6628\"\u003ehypoglycaemia (low risk)\u003c\/strong\u003e, and \u003cstrong data-start=\"6634\" data-end=\"6657\"\u003emitogenic signaling\u003c\/strong\u003e—though this is \u003cstrong data-start=\"6673\" data-end=\"6688\"\u003eunconfirmed\u003c\/strong\u003e for NA-931.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6703\" data-end=\"6846\"\u003e\n\u003cp data-start=\"6705\" data-end=\"6846\"\u003e\u003cstrong data-start=\"6705\" data-end=\"6718\"\u003eUnknowns:\u003c\/strong\u003e \u003cstrong data-start=\"6719\" data-end=\"6739\"\u003eLong-term safety\u003c\/strong\u003e, \u003cstrong data-start=\"6741\" data-end=\"6756\"\u003egallbladder\u003c\/strong\u003e events with large weight loss, \u003cstrong data-start=\"6788\" data-end=\"6809\"\u003epancreato-biliary\u003c\/strong\u003e risks, \u003cstrong data-start=\"6817\" data-end=\"6843\"\u003edrug–drug interactions\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6847\" data-end=\"7065\"\u003e\n\u003cp data-start=\"6849\" data-end=\"7065\"\u003e\u003cstrong data-start=\"6849\" data-end=\"6898\"\u003eContraindications\/caution (by class analogy):\u003c\/strong\u003e History of \u003cstrong data-start=\"6910\" data-end=\"6922\"\u003eMEN2\/MTC\u003c\/strong\u003e (GLP-1 class warning), \u003cstrong data-start=\"6946\" data-end=\"6963\"\u003egastroparesis\u003c\/strong\u003e, pregnancy. Final labeling, if any, will determine specifics. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"7067\" data-end=\"7103\"\u003e\u003cstrong data-start=\"7067\" data-end=\"7103\"\u003eComparative snapshot (tentative)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"7105\" data-end=\"7544\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"7105\" data-end=\"7178\"\u003e\n\u003ctr data-start=\"7105\" data-end=\"7178\"\u003e\n\u003cth data-start=\"7105\" data-end=\"7115\" data-col-size=\"sm\"\u003eFeature\u003c\/th\u003e\n\u003cth data-start=\"7115\" data-end=\"7141\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7117\" data-end=\"7140\"\u003eBioglutide (NA-931)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"7141\" data-end=\"7159\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7143\" data-end=\"7158\"\u003eTirzepatide\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"7159\" data-end=\"7178\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7161\" data-end=\"7176\"\u003eSemaglutide\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"7197\" data-end=\"7544\"\u003e\n\u003ctr data-start=\"7197\" data-end=\"7284\"\u003e\n\u003ctd data-start=\"7197\" data-end=\"7208\" data-col-size=\"sm\"\u003eModality\u003c\/td\u003e\n\u003ctd data-start=\"7208\" data-end=\"7234\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7210\" data-end=\"7233\"\u003eOral small molecule\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"7234\" data-end=\"7255\" data-col-size=\"sm\"\u003eInjectable peptide\u003c\/td\u003e\n\u003ctd data-start=\"7255\" data-end=\"7284\" data-col-size=\"sm\"\u003eOral \u0026amp; injectable peptide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7285\" data-end=\"7357\"\u003e\n\u003ctd data-start=\"7285\" data-end=\"7295\" data-col-size=\"sm\"\u003eTargets\u003c\/td\u003e\n\u003ctd data-start=\"7295\" data-end=\"7334\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7297\" data-end=\"7333\"\u003eGLP-1\/GIP\/GCGR + IGF-1 (claimed)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"7334\" data-end=\"7348\" data-col-size=\"sm\"\u003eGLP-1 + GIP\u003c\/td\u003e\n\u003ctd data-start=\"7348\" data-end=\"7357\" data-col-size=\"sm\"\u003eGLP-1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7358\" data-end=\"7485\"\u003e\n\u003ctd data-start=\"7358\" data-end=\"7382\" data-col-size=\"sm\"\u003eWeight-loss magnitude\u003c\/td\u003e\n\u003ctd data-start=\"7382\" data-end=\"7428\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7384\" data-end=\"7427\"\u003eCompany-reported double-digit at 13 wks\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"7428\" data-end=\"7454\" data-col-size=\"sm\"\u003e15–22% at 72 wks (RCTs)\u003c\/td\u003e\n\u003ctd data-start=\"7454\" data-end=\"7485\" data-col-size=\"sm\"\u003e12–17% at 68–104 wks (RCTs)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7486\" data-end=\"7544\"\u003e\n\u003ctd data-start=\"7486\" data-end=\"7511\" data-col-size=\"sm\"\u003ePeer-reviewed evidence\u003c\/td\u003e\n\u003ctd data-start=\"7511\" data-end=\"7525\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7513\" data-end=\"7524\"\u003eNot yet\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"7525\" data-end=\"7534\" data-col-size=\"sm\"\u003eRobust\u003c\/td\u003e\n\u003ctd data-start=\"7534\" data-end=\"7544\" data-col-size=\"sm\"\u003eRobust\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"7546\" data-end=\"7549\"\u003e\n\u003ch2 data-start=\"7551\" data-end=\"7577\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-start=\"7579\" data-end=\"7805\"\u003e\n\u003cli data-start=\"7579\" data-end=\"7632\"\u003e\n\u003cp data-start=\"7581\" data-end=\"7632\"\u003e\u003cstrong data-start=\"7581\" data-end=\"7597\"\u003eNot approved\u003c\/strong\u003e by FDA\/EMA; \u003cstrong data-start=\"7610\" data-end=\"7629\"\u003einvestigational\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7633\" data-end=\"7805\"\u003e\n\u003cp data-start=\"7635\" data-end=\"7805\"\u003ePublic materials describe \u003cstrong data-start=\"7661\" data-end=\"7677\"\u003ePhase 2→2b\/3\u003c\/strong\u003e programs in \u003cstrong data-start=\"7690\" data-end=\"7701\"\u003eobesity\u003c\/strong\u003e and \u003cstrong data-start=\"7706\" data-end=\"7713\"\u003eT2D\u003c\/strong\u003e, with additional studies proposed (e.g., \u003cstrong data-start=\"7755\" data-end=\"7763\"\u003eMASH\u003c\/strong\u003e). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003ca href=\"https:\/\/www.primetherapeutics.com\/w\/what-s-next-in-the-glp-1-pipeline-prime-s-clinical-team-shares-the-latest?utm_source=chatgpt.com\" rel=\"noopener\" alt=\"https:\/\/www.primetherapeutics.com\/w\/what-s-next-in-the-glp-1-pipeline-prime-s-clinical-team-shares-the-latest?utm_source=chatgpt.com\" class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]!\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between\"\u003e\u003cspan class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"7807\" data-end=\"7810\"\u003e\n\u003ch2 data-start=\"7812\" data-end=\"7842\"\u003e8. Practical Take \u003c\/h2\u003e\n\u003cul data-start=\"7844\" data-end=\"8346\"\u003e\n\u003cli data-start=\"7844\" data-end=\"7971\"\u003e\n\u003cp data-start=\"7846\" data-end=\"7971\"\u003e\u003cstrong data-start=\"7846\" data-end=\"7867\"\u003ePromising concept\u003c\/strong\u003e, but \u003cstrong data-start=\"7873\" data-end=\"7897\"\u003eextraordinary claims\u003c\/strong\u003e (quadruple agonism incl. \u003cstrong data-start=\"7923\" data-end=\"7933\"\u003eIGF-1R\u003c\/strong\u003e) demand \u003cstrong data-start=\"7942\" data-end=\"7968\"\u003eextraordinary evidence\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7972\" data-end=\"8172\"\u003e\n\u003cp data-start=\"7974\" data-end=\"8172\"\u003eUntil \u003cstrong data-start=\"7980\" data-end=\"8011\"\u003epeer-reviewed trial reports\u003c\/strong\u003e with detailed methods, safety tables, pharmacokinetics, and receptor pharmacology are available, treat Bioglutide’s efficacy and mechanism as \u003cstrong data-start=\"8154\" data-end=\"8169\"\u003eprovisional\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8173\" data-end=\"8346\"\u003e\n\u003cp data-start=\"8175\" data-end=\"8346\"\u003eFor patients today, \u003cstrong data-start=\"8195\" data-end=\"8226\"\u003eapproved incretin therapies\u003c\/strong\u003e (semaglutide, tirzepatide, etc.) remain the \u003cstrong data-start=\"8271\" data-end=\"8289\"\u003eevidence-based\u003c\/strong\u003echoices; Bioglutide is a \u003cstrong data-start=\"8315\" data-end=\"8335\"\u003ewatch-this-space\u003c\/strong\u003e candidate.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"8348\" data-end=\"8351\"\u003e\n\u003ch3 data-start=\"8353\" data-end=\"8376\"\u003eSelected References\u003c\/h3\u003e\n\u003cul data-start=\"8378\" data-end=\"9089\"\u003e\n\u003cli data-start=\"8378\" data-end=\"8574\"\u003e\n\u003cp data-start=\"8380\" data-end=\"8574\"\u003e\u003cstrong data-start=\"8380\" data-end=\"8402\"\u003eCompany materials:\u003c\/strong\u003e Biomed Industries—NA-931 (Bioglutide) product page, press releases, and Phase-2 summaries (quadruple agonist, oral, obesity\/T2D). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8575\" data-end=\"8717\"\u003e\n\u003cp data-start=\"8577\" data-end=\"8717\"\u003e\u003cstrong data-start=\"8577\" data-end=\"8599\"\u003eIndustry coverage:\u003c\/strong\u003e FirstWord Pharma news on NA-931 program updates and claimed trial readouts. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003ca href=\"https:\/\/firstwordpharma.com\/story\/5991011?utm_source=chatgpt.com\" rel=\"noopener\" alt=\"https:\/\/firstwordpharma.com\/story\/5991011?utm_source=chatgpt.com\" class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]!\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between absolute\"\u003e\u003cspan class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8718\" data-end=\"8929\"\u003e\n\u003cp data-start=\"8720\" data-end=\"8929\"\u003e\u003cstrong data-start=\"8720\" data-end=\"8743\"\u003ePipeline round-ups:\u003c\/strong\u003e Prime Therapeutics GLP-1 pipeline brief; Larvol Delta product tracker; Patsnap\/Synapse drug entry summarizing company-reported Phase 2 figures. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003ca href=\"https:\/\/www.primetherapeutics.com\/w\/what-s-next-in-the-glp-1-pipeline-prime-s-clinical-team-shares-the-latest?utm_source=chatgpt.com\" rel=\"noopener\" alt=\"https:\/\/www.primetherapeutics.com\/w\/what-s-next-in-the-glp-1-pipeline-prime-s-clinical-team-shares-the-latest?utm_source=chatgpt.com\" class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]!\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between absolute\"\u003e\u003cspan class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8930\" data-end=\"9089\"\u003e\n\u003cp data-start=\"8932\" data-end=\"9089\"\u003e\u003cstrong data-start=\"8932\" data-end=\"8952\"\u003eContext reviews:\u003c\/strong\u003e Triple-agonist reviews outlining rationale for \u003cstrong data-start=\"9000\" data-end=\"9018\"\u003eGLP-1\/GIP\/GCGR\u003c\/strong\u003e combinations (without IGF-1R).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684850889042,"sku":null,"price":200.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/bioglutide100mg.png?v=1770834837"},{"product_id":"survodutide-10mg-vial","title":"Survodutide 10mg vial","description":"\u003ch3\u003e\n\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                    \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN \u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eCONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003cp data-start=\"79\" data-end=\"626\"\u003e\u003cstrong\u003eSurvodutide\u003c\/strong\u003e is a once-weekly, injectable \u003cstrong data-start=\"120\" data-end=\"200\"\u003edual agonist of the glucagon receptor (GCGR) and the GLP-1 receptor (GLP-1R)\u003c\/strong\u003e being co-developed by Zealand Pharma and Boehringer Ingelheim for obesity, metabolic dysfunction-associated steatohepatitis (MASH), and related cardiometabolic complications. By uniting appetite suppression (via GLP-1R) with a glucagon-driven rise in energy expenditure and hepatic fat mobilisation, it aims to deliver larger, metabolically healthier weight loss than GLP-1-only drugs. \u003cmeta charset=\"UTF-8\"\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_80l1q_1\"\u003e\n\u003cdiv class=\"_tableWrapper_80l1q_14 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"65\" data-end=\"2388\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"65\" data-end=\"95\"\u003e\n\u003ctr data-start=\"65\" data-end=\"95\"\u003e\n\u003cth data-start=\"67\" data-end=\"77\" data-col-size=\"md\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-start=\"77\" data-end=\"95\" data-col-size=\"xl\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"110\" data-end=\"2388\"\u003e\n\u003ctr data-start=\"110\" data-end=\"373\"\u003e\n\u003ctd data-start=\"110\" data-end=\"116\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"111\" data-end=\"116\"\u003e1\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"116\" data-end=\"143\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"117\" data-end=\"143\"\u003eLiver disease reversal\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"143\" data-end=\"373\" data-col-size=\"xl\"\u003eIn the Phase 2 MASH study, 83 % of patients achieved complete histologic resolution and one-third showed ≥1-stage fibrosis regression after 48 weeks—rates not yet matched by GLP-1–only drugs\u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"374\" data-end=\"641\"\u003e\n\u003ctd data-start=\"374\" data-end=\"380\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"375\" data-end=\"380\"\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"380\" data-end=\"408\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"381\" data-end=\"408\"\u003ePowerful lipid lowering\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"408\" data-end=\"641\" data-col-size=\"xl\"\u003eExploratory analyses reported triglyceride falls of up to 75 %, free-fatty-acid drops of 49 %, and modest LDL\/VLDL reductions, pointing to a cardiometabolic benefit that goes beyond weight loss.\u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"642\" data-end=\"879\"\u003e\n\u003ctd data-start=\"642\" data-end=\"648\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"643\" data-end=\"648\"\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"648\" data-end=\"677\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"649\" data-end=\"677\"\u003eBlood-pressure reduction\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"677\" data-end=\"879\" data-col-size=\"xl\"\u003eMean systolic\/diastolic BP fell by roughly 10\/5 mmHg alongside a 17 cm shrinkage in waist circumference—clinically relevant for hypertension and visceral-fat risk.\u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"880\" data-end=\"1160\"\u003e\n\u003ctd data-start=\"880\" data-end=\"886\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"881\" data-end=\"886\"\u003e4\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"886\" data-end=\"916\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"887\" data-end=\"916\"\u003eHigher energy expenditure\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"916\" data-end=\"1160\" data-col-size=\"xl\"\u003ePre-clinical work with BI 456906 shows a ~10 % rise in resting metabolic rate, suggesting the dual agonist can counteract the adaptive metabolic slowdown seen with calorie-restriction or GLP-1 monotherapy.\u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1161\" data-end=\"1403\"\u003e\n\u003ctd data-start=\"1161\" data-end=\"1167\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"1162\" data-end=\"1167\"\u003e5\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1167\" data-end=\"1194\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1168\" data-end=\"1194\"\u003eLean-mass preservation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1194\" data-end=\"1403\" data-col-size=\"xl\"\u003eMRI sub-studies indicate that the majority of weight lost is adipose tissue, with lean-mass loss proportionally lower than the ≈25 % seen after diet or bariatric surgery.\u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1404\" data-end=\"1626\"\u003e\n\u003ctd data-start=\"1404\" data-end=\"1410\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"1405\" data-end=\"1410\"\u003e6\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1410\" data-end=\"1452\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1411\" data-end=\"1452\"\u003eEarly glycaemic gains in pre-diabetes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1452\" data-end=\"1626\" data-col-size=\"xl\"\u003eParticipants with HbA1c 5.7–6.5 % saw fasting-glucose drops of up to 13 mg\/dL by week 46, before substantial weight had even been lost.\u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1627\" data-end=\"1907\"\u003e\n\u003ctd data-start=\"1627\" data-end=\"1633\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"1628\" data-end=\"1633\"\u003e7\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1633\" data-end=\"1661\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1634\" data-end=\"1661\"\u003eCardiac function signal\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1661\" data-end=\"1907\" data-col-size=\"xl\"\u003eIn a diet-induced-obese hamster HFpEF model, survodutide improved diastolic function and lipid parameters independent of weight change, supporting the rationale for the ongoing cardiovascular-outcomes trial.\u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1908\" data-end=\"2132\"\u003e\n\u003ctd data-start=\"1908\" data-end=\"1914\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"1909\" data-end=\"1914\"\u003e8\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1914\" data-end=\"1949\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1915\" data-end=\"1949\"\u003eDurable visceral-fat shrinkage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1949\" data-end=\"2132\" data-col-size=\"xl\"\u003eA meta-analysis (1 029 participants) found average waist-circumference reductions of 8.4 cm, scaling with dose (\u0026gt;2 mg) and exposure (\u0026gt;16 weeks).\u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2133\" data-end=\"2388\"\u003e\n\u003ctd data-start=\"2133\" data-end=\"2139\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"2134\" data-end=\"2139\"\u003e9\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2139\" data-end=\"2192\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2140\" data-end=\"2192\"\u003eMedication de-intensification in type 2 diabetes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2192\" data-end=\"2388\" data-col-size=\"xl\"\u003eIn Phase 2 diabetes cohorts, HbA1c fell by up to 1.6 % within 16 weeks, allowing one-third of subjects to down-titrate or stop other glucose-lowering agents.\u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cdiv class=\"sticky end-(--thread-content-margin) h-0 self-end select-none\"\u003e\n\u003cdiv class=\"absolute end-0 flex items-end\"\u003e\u003cspan class=\"\" data-state=\"closed\"\u003e\u003cbutton aria-label=\"Tabel kopiëren\" class=\"hover:bg-token-bg-tertiary text-token-text-secondary my-1 rounded-sm p-1 transition-opacity group-[:not(:hover):not(:focus-within)]:pointer-events-none group-[:not(:hover):not(:focus-within)]:opacity-0\"\u003e\u003csvg width=\"20\" height=\"20\" viewbox=\"0 0 20 20\" fill=\"currentColor\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"icon\"\u003e\u003cpath d=\"M12.668 10.667C12.668 9.95614 12.668 9.46258 12.6367 9.0791C12.6137 8.79732 12.5758 8.60761 12.5244 8.46387L12.4688 8.33399C12.3148 8.03193 12.0803 7.77885 11.793 7.60254L11.666 7.53125C11.508 7.45087 11.2963 7.39395 10.9209 7.36328C10.5374 7.33197 10.0439 7.33203 9.33301 7.33203H6.5C5.78896 7.33203 5.29563 7.33195 4.91211 7.36328C4.63016 7.38632 4.44065 7.42413 4.29688 7.47559L4.16699 7.53125C3.86488 7.68518 3.61186 7.9196 3.43555 8.20703L3.36524 8.33399C3.28478 8.49198 3.22795 8.70352 3.19727 9.0791C3.16595 9.46259 3.16504 9.95611 3.16504 10.667V13.5C3.16504 14.211 3.16593 14.7044 3.19727 15.0879C3.22797 15.4636 3.28473 15.675 3.36524 15.833L3.43555 15.959C3.61186 16.2466 3.86474 16.4807 4.16699 16.6348L4.29688 16.6914C4.44063 16.7428 4.63025 16.7797 4.91211 16.8027C5.29563 16.8341 5.78896 16.835 6.5 16.835H9.33301C10.0439 16.835 10.5374 16.8341 10.9209 16.8027C11.2965 16.772 11.508 16.7152 11.666 16.6348L11.793 16.5645C12.0804 16.3881 12.3148 16.1351 12.4688 15.833L12.5244 15.7031C12.5759 15.5594 12.6137 15.3698 12.6367 15.0879C12.6681 14.7044 12.668 14.211 12.668 13.5V10.667ZM13.998 12.665C14.4528 12.6634 14.8011 12.6602 15.0879 12.6367C15.4635 12.606 15.675 12.5492 15.833 12.4688L15.959 12.3975C16.2466 12.2211 16.4808 11.9682 16.6348 11.666L16.6914 11.5361C16.7428 11.3924 16.7797 11.2026 16.8027 10.9209C16.8341 10.5374 16.835 10.0439 16.835 9.33301V6.5C16.835 5.78896 16.8341 5.29563 16.8027 4.91211C16.7797 4.63025 16.7428 4.44063 16.6914 4.29688L16.6348 4.16699C16.4807 3.86474 16.2466 3.61186 15.959 3.43555L15.833 3.36524C15.675 3.28473 15.4636 3.22797 15.0879 3.19727C14.7044 3.16593 14.211 3.16504 13.5 3.16504H10.667C9.9561 3.16504 9.46259 3.16595 9.0791 3.19727C8.79739 3.22028 8.6076 3.2572 8.46387 3.30859L8.33399 3.36524C8.03176 3.51923 7.77886 3.75343 7.60254 4.04102L7.53125 4.16699C7.4508 4.32498 7.39397 4.53655 7.36328 4.91211C7.33985 5.19893 7.33562 5.54719 7.33399 6.00195H9.33301C10.022 6.00195 10.5791 6.00131 11.0293 6.03809C11.4873 6.07551 11.8937 6.15471 12.2705 6.34668L12.4883 6.46875C12.984 6.7728 13.3878 7.20854 13.6533 7.72949L13.7197 7.87207C13.8642 8.20859 13.9292 8.56974 13.9619 8.9707C13.9987 9.42092 13.998 9.97799 13.998 10.667V12.665ZM18.165 9.33301C18.165 10.022 18.1657 10.5791 18.1289 11.0293C18.0961 11.4302 18.0311 11.7914 17.8867 12.1279L17.8203 12.2705C17.5549 12.7914 17.1509 13.2272 16.6553 13.5313L16.4365 13.6533C16.0599 13.8452 15.6541 13.9245 15.1963 13.9619C14.8593 13.9895 14.4624 13.9935 13.9951 13.9951C13.9935 14.4624 13.9895 14.8593 13.9619 15.1963C13.9292 15.597 13.864 15.9576 13.7197 16.2939L13.6533 16.4365C13.3878 16.9576 12.9841 17.3941 12.4883 17.6982L12.2705 17.8203C11.8937 18.0123 11.4873 18.0915 11.0293 18.1289C10.5791 18.1657 10.022 18.165 9.33301 18.165H6.5C5.81091 18.165 5.25395 18.1657 4.80371 18.1289C4.40306 18.0962 4.04235 18.031 3.70606 17.8867L3.56348 17.8203C3.04244 17.5548 2.60585 17.151 2.30176 16.6553L2.17969 16.4365C1.98788 16.0599 1.90851 15.6541 1.87109 15.1963C1.83431 14.746 1.83496 14.1891 1.83496 13.5V10.667C1.83496 9.978 1.83432 9.42091 1.87109 8.9707C1.90851 8.5127 1.98772 8.10625 2.17969 7.72949L2.30176 7.51172C2.60586 7.0159 3.04236 6.6122 3.56348 6.34668L3.70606 6.28027C4.04237 6.136 4.40303 6.07083 4.80371 6.03809C5.14051 6.01057 5.53708 6.00551 6.00391 6.00391C6.00551 5.53708 6.01057 5.14051 6.03809 4.80371C6.0755 4.34588 6.15483 3.94012 6.34668 3.56348L6.46875 3.34473C6.77282 2.84912 7.20856 2.44514 7.72949 2.17969L7.87207 2.11328C8.20855 1.96886 8.56979 1.90385 8.9707 1.87109C9.42091 1.83432 9.978 1.83496 10.667 1.83496H13.5C14.1891 1.83496 14.746 1.83431 15.1963 1.87109C15.6541 1.90851 16.0599 1.98788 16.4365 2.17969L16.6553 2.30176C17.151 2.60585 17.5548 3.04244 17.8203 3.56348L17.8867 3.70606C18.031 4.04235 18.0962 4.40306 18.1289 4.80371C18.1657 5.25395 18.165 5.81091 18.165 6.5V9.33301Z\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\u003c\/button\u003e\u003c\/span\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"628\" data-end=\"631\"\u003e\n\u003ch3 data-start=\"633\" data-end=\"663\"\u003e2. Pre-clinical insights\u003c\/h3\u003e\n\u003cp data-start=\"664\" data-end=\"1040\"\u003eRodent models fed a high-fat diet showed that survodutide \u003cstrong data-start=\"722\" data-end=\"760\"\u003eincreased total energy expenditure\u003c\/strong\u003e, lowered body weight and improved glycaemic control more than either semaglutide or long-acting glucagon analogues alone. Mechanistically, hepatic GCGR activation ramped up β-oxidation and thermogenesis, while GLP-1R agonism curbed intake. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"1042\" data-end=\"1045\"\u003e\n\u003ch3 data-start=\"1047\" data-end=\"1091\"\u003e3. Pharmacokinetics \u0026amp; dosing principle\u003c\/h3\u003e\n\u003cp data-start=\"1092\" data-end=\"1428\"\u003eA proprietary fatty-acid side-chain extends half-life to ≈5 days, enabling once-weekly SC administration. Phase 1 studies established linear PK, no significant accumulation, and a tolerability-guided step-up schedule now standard in late-stage trials (0.3 mg start, titrated to 3.6 mg or 6.0 mg). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"1430\" data-end=\"1433\"\u003e\n\u003ch3 data-start=\"1435\" data-end=\"1468\"\u003e4. Clinical evidence so far\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_80l1q_1\"\u003e\n\u003cdiv class=\"_tableWrapper_80l1q_14 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"1470\" data-end=\"2082\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"1470\" data-end=\"1555\"\u003e\n\u003ctr data-start=\"1470\" data-end=\"1555\"\u003e\n\u003cth data-start=\"1470\" data-end=\"1483\" data-col-size=\"sm\"\u003eIndication\u003c\/th\u003e\n\u003cth data-start=\"1483\" data-end=\"1503\" data-col-size=\"sm\"\u003eKey study (phase)\u003c\/th\u003e\n\u003cth data-start=\"1503\" data-end=\"1523\" data-col-size=\"sm\"\u003ePopulation \u0026amp; dose\u003c\/th\u003e\n\u003cth data-start=\"1523\" data-end=\"1534\" data-col-size=\"sm\"\u003eDuration\u003c\/th\u003e\n\u003cth data-start=\"1534\" data-end=\"1555\" data-col-size=\"md\"\u003eTop-line efficacy\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"1641\" data-end=\"2082\"\u003e\n\u003ctr data-start=\"1641\" data-end=\"1810\"\u003e\n\u003ctd data-start=\"1641\" data-end=\"1669\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"1643\" data-end=\"1668\"\u003eObesity (no diabetes)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1669\" data-end=\"1693\" data-col-size=\"sm\"\u003eNCT04667377 (Phase 2)\u003c\/td\u003e\n\u003ctd data-start=\"1693\" data-end=\"1723\" data-col-size=\"sm\"\u003e4 weekly doses up to 4.8 mg\u003c\/td\u003e\n\u003ctd data-start=\"1723\" data-end=\"1730\" data-col-size=\"sm\"\u003e46 w\u003c\/td\u003e\n\u003ctd data-start=\"1730\" data-end=\"1810\" data-col-size=\"md\"\u003e−18.7 % mean weight in 4.8 mg completers; ≥15 % loss in 55 % of all-comers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1811\" data-end=\"1920\"\u003e\n\u003ctd data-start=\"1811\" data-end=\"1833\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"1813\" data-end=\"1832\"\u003eType 2 diabetes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1833\" data-end=\"1854\" data-col-size=\"sm\"\u003eRandomised Phase 2\u003c\/td\u003e\n\u003ctd data-start=\"1854\" data-end=\"1867\" data-col-size=\"sm\"\u003e0.6–3.6 mg\u003c\/td\u003e\n\u003ctd data-start=\"1867\" data-end=\"1874\" data-col-size=\"sm\"\u003e16 w\u003c\/td\u003e\n\u003ctd data-start=\"1874\" data-end=\"1920\" data-col-size=\"md\"\u003eHbA1c −1.6 % and weight −8.7 % at 3.6 mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1921\" data-end=\"2082\"\u003e\n\u003ctd data-start=\"1921\" data-end=\"1952\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"1923\" data-end=\"1951\"\u003eMASH with F2–F3 fibrosis\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1952\" data-end=\"1969\" data-col-size=\"sm\"\u003ePhase 2 (NEJM)\u003c\/td\u003e\n\u003ctd data-start=\"1969\" data-end=\"1982\" data-col-size=\"sm\"\u003e2.4–6.0 mg\u003c\/td\u003e\n\u003ctd data-start=\"1982\" data-end=\"1989\" data-col-size=\"sm\"\u003e48 w\u003c\/td\u003e\n\u003ctd data-start=\"1989\" data-end=\"2082\" data-col-size=\"md\"\u003e83 % histologic MASH resolution vs 18 % placebo; ≥1-stage fibrosis improvement in 34–36 %\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cdiv class=\"sticky end-(--thread-content-margin) h-0 self-end select-none\"\u003e\n\u003cdiv class=\"absolute end-0 flex items-end\"\u003e\u003cspan class=\"\" data-state=\"closed\"\u003e\u003cbutton aria-label=\"Tabel kopiëren\" class=\"hover:bg-token-bg-tertiary text-token-text-secondary my-1 rounded-sm p-1 transition-opacity group-[:not(:hover):not(:focus-within)]:pointer-events-none group-[:not(:hover):not(:focus-within)]:opacity-0\"\u003e\u003csvg width=\"20\" height=\"20\" viewbox=\"0 0 20 20\" fill=\"currentColor\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"icon\"\u003e\u003cpath d=\"M12.668 10.667C12.668 9.95614 12.668 9.46258 12.6367 9.0791C12.6137 8.79732 12.5758 8.60761 12.5244 8.46387L12.4688 8.33399C12.3148 8.03193 12.0803 7.77885 11.793 7.60254L11.666 7.53125C11.508 7.45087 11.2963 7.39395 10.9209 7.36328C10.5374 7.33197 10.0439 7.33203 9.33301 7.33203H6.5C5.78896 7.33203 5.29563 7.33195 4.91211 7.36328C4.63016 7.38632 4.44065 7.42413 4.29688 7.47559L4.16699 7.53125C3.86488 7.68518 3.61186 7.9196 3.43555 8.20703L3.36524 8.33399C3.28478 8.49198 3.22795 8.70352 3.19727 9.0791C3.16595 9.46259 3.16504 9.95611 3.16504 10.667V13.5C3.16504 14.211 3.16593 14.7044 3.19727 15.0879C3.22797 15.4636 3.28473 15.675 3.36524 15.833L3.43555 15.959C3.61186 16.2466 3.86474 16.4807 4.16699 16.6348L4.29688 16.6914C4.44063 16.7428 4.63025 16.7797 4.91211 16.8027C5.29563 16.8341 5.78896 16.835 6.5 16.835H9.33301C10.0439 16.835 10.5374 16.8341 10.9209 16.8027C11.2965 16.772 11.508 16.7152 11.666 16.6348L11.793 16.5645C12.0804 16.3881 12.3148 16.1351 12.4688 15.833L12.5244 15.7031C12.5759 15.5594 12.6137 15.3698 12.6367 15.0879C12.6681 14.7044 12.668 14.211 12.668 13.5V10.667ZM13.998 12.665C14.4528 12.6634 14.8011 12.6602 15.0879 12.6367C15.4635 12.606 15.675 12.5492 15.833 12.4688L15.959 12.3975C16.2466 12.2211 16.4808 11.9682 16.6348 11.666L16.6914 11.5361C16.7428 11.3924 16.7797 11.2026 16.8027 10.9209C16.8341 10.5374 16.835 10.0439 16.835 9.33301V6.5C16.835 5.78896 16.8341 5.29563 16.8027 4.91211C16.7797 4.63025 16.7428 4.44063 16.6914 4.29688L16.6348 4.16699C16.4807 3.86474 16.2466 3.61186 15.959 3.43555L15.833 3.36524C15.675 3.28473 15.4636 3.22797 15.0879 3.19727C14.7044 3.16593 14.211 3.16504 13.5 3.16504H10.667C9.9561 3.16504 9.46259 3.16595 9.0791 3.19727C8.79739 3.22028 8.6076 3.2572 8.46387 3.30859L8.33399 3.36524C8.03176 3.51923 7.77886 3.75343 7.60254 4.04102L7.53125 4.16699C7.4508 4.32498 7.39397 4.53655 7.36328 4.91211C7.33985 5.19893 7.33562 5.54719 7.33399 6.00195H9.33301C10.022 6.00195 10.5791 6.00131 11.0293 6.03809C11.4873 6.07551 11.8937 6.15471 12.2705 6.34668L12.4883 6.46875C12.984 6.7728 13.3878 7.20854 13.6533 7.72949L13.7197 7.87207C13.8642 8.20859 13.9292 8.56974 13.9619 8.9707C13.9987 9.42092 13.998 9.97799 13.998 10.667V12.665ZM18.165 9.33301C18.165 10.022 18.1657 10.5791 18.1289 11.0293C18.0961 11.4302 18.0311 11.7914 17.8867 12.1279L17.8203 12.2705C17.5549 12.7914 17.1509 13.2272 16.6553 13.5313L16.4365 13.6533C16.0599 13.8452 15.6541 13.9245 15.1963 13.9619C14.8593 13.9895 14.4624 13.9935 13.9951 13.9951C13.9935 14.4624 13.9895 14.8593 13.9619 15.1963C13.9292 15.597 13.864 15.9576 13.7197 16.2939L13.6533 16.4365C13.3878 16.9576 12.9841 17.3941 12.4883 17.6982L12.2705 17.8203C11.8937 18.0123 11.4873 18.0915 11.0293 18.1289C10.5791 18.1657 10.022 18.165 9.33301 18.165H6.5C5.81091 18.165 5.25395 18.1657 4.80371 18.1289C4.40306 18.0962 4.04235 18.031 3.70606 17.8867L3.56348 17.8203C3.04244 17.5548 2.60585 17.151 2.30176 16.6553L2.17969 16.4365C1.98788 16.0599 1.90851 15.6541 1.87109 15.1963C1.83431 14.746 1.83496 14.1891 1.83496 13.5V10.667C1.83496 9.978 1.83432 9.42091 1.87109 8.9707C1.90851 8.5127 1.98772 8.10625 2.17969 7.72949L2.30176 7.51172C2.60586 7.0159 3.04236 6.6122 3.56348 6.34668L3.70606 6.28027C4.04237 6.136 4.40303 6.07083 4.80371 6.03809C5.14051 6.01057 5.53708 6.00551 6.00391 6.00391C6.00551 5.53708 6.01057 5.14051 6.03809 4.80371C6.0755 4.34588 6.15483 3.94012 6.34668 3.56348L6.46875 3.34473C6.77282 2.84912 7.20856 2.44514 7.72949 2.17969L7.87207 2.11328C8.20855 1.96886 8.56979 1.90385 8.9707 1.87109C9.42091 1.83432 9.978 1.83496 10.667 1.83496H13.5C14.1891 1.83496 14.746 1.83431 15.1963 1.87109C15.6541 1.90851 16.0599 1.98788 16.4365 2.17969L16.6553 2.30176C17.151 2.60585 17.5548 3.04244 17.8203 3.56348L17.8867 3.70606C18.031 4.04235 18.0962 4.40306 18.1289 4.80371C18.1657 5.25395 18.165 5.81091 18.165 6.5V9.33301Z\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\u003c\/button\u003e\u003c\/span\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp data-start=\"2084\" data-end=\"2245\"\u003e\u003cem data-start=\"2084\" data-end=\"2107\"\u003eObesity trial sources\u003c\/em\u003e \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003ca href=\"https:\/\/www.ajmc.com\/view\/patients-with-overweight-or-obesity-show-significant-weight-loss-in-phase-2-survodutide-trial?utm_source=chatgpt.com\" rel=\"noopener\" alt=\"https:\/\/www.ajmc.com\/view\/patients-with-overweight-or-obesity-show-significant-weight-loss-in-phase-2-survodutide-trial?utm_source=chatgpt.com\" class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! transition-colors duration-150 ease-in-out\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between overflow-hidden\"\u003e\u003cspan class=\"max-w-full grow truncate overflow-hidden text-center\"\u003eAJMC\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003ca href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11664303\/?utm_source=chatgpt.com\" rel=\"noopener\" alt=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11664303\/?utm_source=chatgpt.com\" class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! transition-colors duration-150 ease-in-out\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between overflow-hidden\"\u003e\u003cspan class=\"max-w-full grow truncate overflow-hidden text-center\"\u003ePMC\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/span\u003e – \u003cem data-start=\"2148\" data-end=\"2158\"\u003eDiabetes\u003c\/em\u003e \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003ca href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10844353\/?utm_source=chatgpt.com\" rel=\"noopener\" alt=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10844353\/?utm_source=chatgpt.com\" class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! transition-colors duration-150 ease-in-out\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between overflow-hidden\"\u003e\u003cspan class=\"max-w-full grow truncate overflow-hidden text-center\"\u003ePMC\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/span\u003e – \u003cem data-start=\"2199\" data-end=\"2205\"\u003eMASH\u003c\/em\u003e \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003ca href=\"https:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2401755?utm_source=chatgpt.com\" rel=\"noopener\" alt=\"https:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2401755?utm_source=chatgpt.com\" class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! transition-colors duration-150 ease-in-out\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between overflow-hidden\"\u003e\u003cspan class=\"max-w-full grow truncate overflow-hidden text-center\"\u003eNew England Journal of Medicine\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38847460\/?utm_source=chatgpt.com\" rel=\"noopener\" alt=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38847460\/?utm_source=chatgpt.com\" class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! transition-colors duration-150 ease-in-out\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between overflow-hidden\"\u003e\u003cspan class=\"max-w-full grow truncate overflow-hidden text-center\"\u003ePubMed\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003ca href=\"https:\/\/www.ft.com\/content\/0a75f311-f960-4f81-9c11-00e14923ecef?utm_source=chatgpt.com\" rel=\"noopener\" alt=\"https:\/\/www.ft.com\/content\/0a75f311-f960-4f81-9c11-00e14923ecef?utm_source=chatgpt.com\" class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! transition-colors duration-150 ease-in-out\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between overflow-hidden\"\u003e\u003cspan class=\"max-w-full grow truncate overflow-hidden text-center\"\u003eFinancial Times\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-start=\"2247\" data-end=\"2569\"\u003e\u003cstrong data-start=\"2247\" data-end=\"2265\"\u003eSafety profile\u003c\/strong\u003e – Across trials, gastrointestinal events dominate (nausea ≈ 66 %, vomiting ≈ 41 %, diarrhoea ≈ 49 % at therapeutic doses). Serious AEs were comparable to placebo, but discontinuation risk is ~4-fold higher than placebo—driving the lengthened titration in phase 3. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38847460\/?utm_source=chatgpt.com\" rel=\"noopener\" alt=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38847460\/?utm_source=chatgpt.com\" class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! transition-colors duration-150 ease-in-out\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between overflow-hidden\"\u003e\u003cspan class=\"max-w-full grow truncate overflow-hidden text-center\"\u003ePubMed\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003ca href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12184113\/?utm_source=chatgpt.com\" rel=\"noopener\" alt=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12184113\/?utm_source=chatgpt.com\" class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! transition-colors duration-150 ease-in-out\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between overflow-hidden\"\u003e\u003cspan class=\"max-w-full grow truncate overflow-hidden text-center\"\u003ePMC\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"2571\" data-end=\"2574\"\u003e\n\u003ch3 data-start=\"2576\" data-end=\"2614\"\u003e5. Phase 3 programme (2025 status)\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_80l1q_1\"\u003e\n\u003cdiv class=\"_tableWrapper_80l1q_14 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"2616\" data-end=\"3345\" class=\"w-fit min-w-(--thread-content-width)\" style=\"width: 100%;\"\u003e\n\u003cthead data-start=\"2616\" data-end=\"2689\"\u003e\n\u003ctr data-start=\"2616\" data-end=\"2689\"\u003e\n\u003cth data-start=\"2616\" data-end=\"2628\" data-col-size=\"sm\" style=\"width: 20.418848%;\"\u003eProgramme\u003c\/th\u003e\n\u003cth data-start=\"2628\" data-end=\"2648\" data-col-size=\"sm\" style=\"width: 22.862129%;\"\u003eTarget cohort (N)\u003c\/th\u003e\n\u003cth data-start=\"2648\" data-end=\"2668\" data-col-size=\"sm\" style=\"width: 27.34684%;\"\u003ePrimary end-point\u003c\/th\u003e\n\u003cth data-start=\"2668\" data-end=\"2689\" data-col-size=\"md\" style=\"width: 27.626982%;\"\u003eStatus \/ read-out\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"2764\" data-end=\"3345\"\u003e\n\u003ctr data-start=\"2764\" data-end=\"2927\"\u003e\n\u003ctd data-start=\"2764\" data-end=\"2784\" data-col-size=\"sm\" style=\"width: 20.418848%;\"\u003e\u003cstrong data-start=\"2766\" data-end=\"2783\"\u003eSYNCHRONIZE-1\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2784\" data-end=\"2811\" data-col-size=\"sm\" style=\"width: 22.862129%;\"\u003eObesity, no T2D (≈ 7 00)\u003c\/td\u003e\n\u003ctd data-start=\"2811\" data-end=\"2849\" data-col-size=\"sm\" style=\"width: 27.34684%;\"\u003e≥ 5 % \u0026amp; ≥ 10 % weight loss at wk 76\u003c\/td\u003e\n\u003ctd data-start=\"2849\" data-end=\"2927\" data-col-size=\"md\" style=\"width: 27.626982%;\"\u003e\n\u003cem data-start=\"2851\" data-end=\"2887\"\u003eLast patient out expected Dec 2025\u003c\/em\u003e \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2928\" data-end=\"2992\"\u003e\n\u003ctd data-start=\"2928\" data-end=\"2948\" data-col-size=\"sm\" style=\"width: 20.418848%;\"\u003e\u003cstrong data-start=\"2930\" data-end=\"2947\"\u003eSYNCHRONIZE-2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2948\" data-end=\"2964\" data-col-size=\"sm\" style=\"width: 22.862129%;\"\u003eObesity + T2D\u003c\/td\u003e\n\u003ctd data-start=\"2964\" data-end=\"2971\" data-col-size=\"sm\" style=\"width: 27.34684%;\"\u003eSame\u003c\/td\u003e\n\u003ctd data-start=\"2971\" data-end=\"2992\" data-col-size=\"md\" style=\"width: 27.626982%;\"\u003eParallel timeline\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2993\" data-end=\"3178\"\u003e\n\u003ctd data-start=\"2993\" data-end=\"3029\" data-col-size=\"sm\" style=\"width: 20.418848%;\"\u003e\u003cstrong data-start=\"2995\" data-end=\"3028\"\u003eLIVERAGE \/ LIVERAGE-Cirrhosis\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3029\" data-end=\"3047\" data-col-size=\"sm\" style=\"width: 22.862129%;\"\u003eMASH F2–F3 \/ F4\u003c\/td\u003e\n\u003ctd data-start=\"3047\" data-end=\"3082\" data-col-size=\"sm\" style=\"width: 27.34684%;\"\u003eHistologic resolution ± fibrosis\u003c\/td\u003e\n\u003ctd data-start=\"3082\" data-end=\"3178\" data-col-size=\"md\" style=\"width: 27.626982%;\"\u003eRecruiting; baseline imaging \u0026amp; NIT poster at EASL 2025 \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3179\" data-end=\"3345\"\u003e\n\u003ctd data-start=\"3179\" data-end=\"3202\" data-col-size=\"sm\" style=\"width: 20.418848%;\"\u003e\u003cstrong data-start=\"3181\" data-end=\"3201\"\u003eSYNCHRONIZE-CVOT\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3202\" data-end=\"3244\" data-col-size=\"sm\" style=\"width: 22.862129%;\"\u003eObesity\/overweight with CV risk (4 935)\u003c\/td\u003e\n\u003ctd data-start=\"3244\" data-end=\"3259\" data-col-size=\"sm\" style=\"width: 27.34684%;\"\u003e5-point MACE\u003c\/td\u003e\n\u003ctd data-start=\"3259\" data-end=\"3345\" data-col-size=\"md\" style=\"width: 27.626982%;\"\u003eActive, not recruiting; last update Jul 2025 \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cdiv class=\"sticky end-(--thread-content-margin) h-0 self-end select-none\"\u003e\n\u003cdiv class=\"absolute end-0 flex items-end\"\u003e\u003cspan class=\"\" data-state=\"closed\"\u003e\u003cbutton aria-label=\"Tabel kopiëren\" class=\"hover:bg-token-bg-tertiary text-token-text-secondary my-1 rounded-sm p-1 transition-opacity group-[:not(:hover):not(:focus-within)]:pointer-events-none group-[:not(:hover):not(:focus-within)]:opacity-0\"\u003e\u003csvg width=\"20\" height=\"20\" viewbox=\"0 0 20 20\" fill=\"currentColor\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"icon\"\u003e\u003cpath d=\"M12.668 10.667C12.668 9.95614 12.668 9.46258 12.6367 9.0791C12.6137 8.79732 12.5758 8.60761 12.5244 8.46387L12.4688 8.33399C12.3148 8.03193 12.0803 7.77885 11.793 7.60254L11.666 7.53125C11.508 7.45087 11.2963 7.39395 10.9209 7.36328C10.5374 7.33197 10.0439 7.33203 9.33301 7.33203H6.5C5.78896 7.33203 5.29563 7.33195 4.91211 7.36328C4.63016 7.38632 4.44065 7.42413 4.29688 7.47559L4.16699 7.53125C3.86488 7.68518 3.61186 7.9196 3.43555 8.20703L3.36524 8.33399C3.28478 8.49198 3.22795 8.70352 3.19727 9.0791C3.16595 9.46259 3.16504 9.95611 3.16504 10.667V13.5C3.16504 14.211 3.16593 14.7044 3.19727 15.0879C3.22797 15.4636 3.28473 15.675 3.36524 15.833L3.43555 15.959C3.61186 16.2466 3.86474 16.4807 4.16699 16.6348L4.29688 16.6914C4.44063 16.7428 4.63025 16.7797 4.91211 16.8027C5.29563 16.8341 5.78896 16.835 6.5 16.835H9.33301C10.0439 16.835 10.5374 16.8341 10.9209 16.8027C11.2965 16.772 11.508 16.7152 11.666 16.6348L11.793 16.5645C12.0804 16.3881 12.3148 16.1351 12.4688 15.833L12.5244 15.7031C12.5759 15.5594 12.6137 15.3698 12.6367 15.0879C12.6681 14.7044 12.668 14.211 12.668 13.5V10.667ZM13.998 12.665C14.4528 12.6634 14.8011 12.6602 15.0879 12.6367C15.4635 12.606 15.675 12.5492 15.833 12.4688L15.959 12.3975C16.2466 12.2211 16.4808 11.9682 16.6348 11.666L16.6914 11.5361C16.7428 11.3924 16.7797 11.2026 16.8027 10.9209C16.8341 10.5374 16.835 10.0439 16.835 9.33301V6.5C16.835 5.78896 16.8341 5.29563 16.8027 4.91211C16.7797 4.63025 16.7428 4.44063 16.6914 4.29688L16.6348 4.16699C16.4807 3.86474 16.2466 3.61186 15.959 3.43555L15.833 3.36524C15.675 3.28473 15.4636 3.22797 15.0879 3.19727C14.7044 3.16593 14.211 3.16504 13.5 3.16504H10.667C9.9561 3.16504 9.46259 3.16595 9.0791 3.19727C8.79739 3.22028 8.6076 3.2572 8.46387 3.30859L8.33399 3.36524C8.03176 3.51923 7.77886 3.75343 7.60254 4.04102L7.53125 4.16699C7.4508 4.32498 7.39397 4.53655 7.36328 4.91211C7.33985 5.19893 7.33562 5.54719 7.33399 6.00195H9.33301C10.022 6.00195 10.5791 6.00131 11.0293 6.03809C11.4873 6.07551 11.8937 6.15471 12.2705 6.34668L12.4883 6.46875C12.984 6.7728 13.3878 7.20854 13.6533 7.72949L13.7197 7.87207C13.8642 8.20859 13.9292 8.56974 13.9619 8.9707C13.9987 9.42092 13.998 9.97799 13.998 10.667V12.665ZM18.165 9.33301C18.165 10.022 18.1657 10.5791 18.1289 11.0293C18.0961 11.4302 18.0311 11.7914 17.8867 12.1279L17.8203 12.2705C17.5549 12.7914 17.1509 13.2272 16.6553 13.5313L16.4365 13.6533C16.0599 13.8452 15.6541 13.9245 15.1963 13.9619C14.8593 13.9895 14.4624 13.9935 13.9951 13.9951C13.9935 14.4624 13.9895 14.8593 13.9619 15.1963C13.9292 15.597 13.864 15.9576 13.7197 16.2939L13.6533 16.4365C13.3878 16.9576 12.9841 17.3941 12.4883 17.6982L12.2705 17.8203C11.8937 18.0123 11.4873 18.0915 11.0293 18.1289C10.5791 18.1657 10.022 18.165 9.33301 18.165H6.5C5.81091 18.165 5.25395 18.1657 4.80371 18.1289C4.40306 18.0962 4.04235 18.031 3.70606 17.8867L3.56348 17.8203C3.04244 17.5548 2.60585 17.151 2.30176 16.6553L2.17969 16.4365C1.98788 16.0599 1.90851 15.6541 1.87109 15.1963C1.83431 14.746 1.83496 14.1891 1.83496 13.5V10.667C1.83496 9.978 1.83432 9.42091 1.87109 8.9707C1.90851 8.5127 1.98772 8.10625 2.17969 7.72949L2.30176 7.51172C2.60586 7.0159 3.04236 6.6122 3.56348 6.34668L3.70606 6.28027C4.04237 6.136 4.40303 6.07083 4.80371 6.03809C5.14051 6.01057 5.53708 6.00551 6.00391 6.00391C6.00551 5.53708 6.01057 5.14051 6.03809 4.80371C6.0755 4.34588 6.15483 3.94012 6.34668 3.56348L6.46875 3.34473C6.77282 2.84912 7.20856 2.44514 7.72949 2.17969L7.87207 2.11328C8.20855 1.96886 8.56979 1.90385 8.9707 1.87109C9.42091 1.83432 9.978 1.83496 10.667 1.83496H13.5C14.1891 1.83496 14.746 1.83431 15.1963 1.87109C15.6541 1.90851 16.0599 1.98788 16.4365 2.17969L16.6553 2.30176C17.151 2.60585 17.5548 3.04244 17.8203 3.56348L17.8867 3.70606C18.031 4.04235 18.0962 4.40306 18.1289 4.80371C18.1657 5.25395 18.165 5.81091 18.165 6.5V9.33301Z\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\u003c\/button\u003e\u003c\/span\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp data-start=\"3347\" data-end=\"3469\"\u003eBoehringer projects first filings \u003cstrong data-start=\"3381\" data-end=\"3395\"\u003ein 2027–28\u003c\/strong\u003e if these trials meet endpoints\u003cmeta charset=\"UTF-8\"\u003e\u003c\/p\u003e\n\u003ch3 data-start=\"2395\" data-end=\"2411\"\u003eReferences\u003c\/h3\u003e\n\u003col data-start=\"2412\" data-end=\"4099\"\u003e\n\u003cli data-start=\"2412\" data-end=\"2579\"\u003e\n\u003cp data-start=\"2415\" data-end=\"2579\"\u003eSanyal AJ et al. \u003cem data-start=\"2432\" data-end=\"2520\"\u003eA Phase 2 Randomized Trial of Survodutide in Adults with MASH and Fibrosis Stages 1–3.\u003c\/em\u003e N Engl J Med 2024.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2412\" data-end=\"2579\"\u003e\n\u003cp data-start=\"2415\" data-end=\"2579\"\u003eLucas KJ et al. “Survodutide Weight Loss Is Associated with Changes in Plasma Free-Fatty Acids and Triglycerides.” ADA abstract 1635-P, 2024; and Le Roux CW et al. \u003cem data-start=\"2747\" data-end=\"2820\"\u003eSurvodutide Improves Cardiometabolic Parameters in Adults with Obesity.\u003c\/em\u003e Eur Heart J Suppl 2024. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2887\" data-end=\"3158\"\u003e\n\u003cp data-start=\"2890\" data-end=\"3158\"\u003eLe Roux CW et al. \u003cem data-start=\"2908\" data-end=\"2981\"\u003eSurvodutide Improves Cardiometabolic Parameters in Adults with Obesity.\u003c\/em\u003e Eur Heart J Suppl 2024; plus Hennige AM et al. “Survodutide: A Promising Agent for Obesity and Type 2 Diabetes.” Auctores Online 2025. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3159\" data-end=\"3334\"\u003e\n\u003cp data-start=\"3162\" data-end=\"3334\"\u003eMüller TD et al. “Discovery and Pre-clinical Pharmacology of the GCGR\/GLP-1R Dual Agonist BI 456906.” \u003cem data-start=\"3264\" data-end=\"3286\"\u003eMolecular Metabolism\u003c\/em\u003e 2023. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3335\" data-end=\"3527\"\u003e\n\u003cp data-start=\"3338\" data-end=\"3527\"\u003eLe Roux CW et al. “Glucagon and GLP-1 Receptor Dual Agonist Survodutide for Obesity: Body-Composition Findings.” \u003cem data-start=\"3451\" data-end=\"3479\"\u003eLancet Diabetes Endocrinol\u003c\/em\u003e 2024. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3528\" data-end=\"3631\"\u003e\n\u003cp data-start=\"3531\" data-end=\"3631\"\u003eAbstract 6926. 19th Cardiometabolic Health Congress, 2024. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3632\" data-end=\"3769\"\u003e\n\u003cp data-start=\"3635\" data-end=\"3769\"\u003eADA 2025 abstract 1704-P. “Survodutide Improves HFpEF and Dyslipidaemia in a Hamster Model.” \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3770\" data-end=\"3955\"\u003e\n\u003cp data-start=\"3773\" data-end=\"3955\"\u003eShi LL et al. “Effect of Survodutide on Weight, BMI and Waist Circumference: Meta-analysis of 18 Study Groups.” \u003cem data-start=\"3885\" data-end=\"3907\"\u003eDiabetol Metab Syndr\u003c\/em\u003e 2024. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3956\" data-end=\"4099\"\u003e\n\u003cp data-start=\"3959\" data-end=\"4099\"\u003eNuijten MAH et al. \u003cem data-start=\"3978\" data-end=\"4043\"\u003eSurvodutide Trial Rationale in Type 2 Diabetes (SYNCHRONIZE-2).\u003c\/em\u003e \u003cem data-start=\"4044\" data-end=\"4053\"\u003eObesity\u003c\/em\u003e 2025.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp data-start=\"3347\" data-end=\"3469\"\u003e \u003c\/p\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684855705938,"sku":null,"price":90.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/Survodutide_10mg.png?v=1770834882"},{"product_id":"sobetiromegc-1","title":"Sobetirome(GC-1) 10.000mcg sublingual\/oral vial","description":"\u003cp data-end=\"724\" data-start=\"187\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                             \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN \u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eCONSUMPTION\u003cmeta charset=\"UTF-8\"\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-start=\"164\" data-end=\"742\"\u003e\u003cstrong\u003eSobetirome\u003c\/strong\u003e is an \u003cstrong data-start=\"214\" data-end=\"265\"\u003eoral, small-molecule TRβ-selective thyromimetic\u003c\/strong\u003e designed to deliver the \u003cstrong data-start=\"290\" data-end=\"345\"\u003elipid-lowering and hepatic\/metabolic benefits of T3\u003c\/strong\u003e while minimizing \u003cstrong data-start=\"363\" data-end=\"404\"\u003eTRα-mediated cardiac and bone effects\u003c\/strong\u003e. By activating \u003cstrong data-start=\"420\" data-end=\"427\"\u003eTRβ\u003c\/strong\u003e(highly expressed in \u003cstrong data-start=\"449\" data-end=\"458\"\u003eliver\u003c\/strong\u003e and \u003cstrong data-start=\"463\" data-end=\"494\"\u003eCNS oligodendrocyte lineage\u003c\/strong\u003e), sobetirome increases \u003cstrong data-start=\"518\" data-end=\"553\"\u003ehepatic LDL-receptor expression\u003c\/strong\u003e, enhances \u003cstrong data-start=\"564\" data-end=\"597\"\u003ereverse cholesterol transport\u003c\/strong\u003e, \u003cstrong data-start=\"599\" data-end=\"634\"\u003estimulates fatty-acid oxidation\u003c\/strong\u003e, and \u003cstrong data-start=\"640\" data-end=\"691\"\u003ereprograms bile-acid and lipoprotein metabolism\u003c\/strong\u003e. It is \u003cstrong data-start=\"699\" data-end=\"718\"\u003einvestigational\u003c\/strong\u003e (not FDA\/EMA-approved).\u003c\/p\u003e\n\u003chr data-start=\"744\" data-end=\"747\"\u003e\n\u003ch3 data-start=\"749\" data-end=\"810\"\u003eAdditional Benefits of Sobetirome Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"812\" data-end=\"3128\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"812\" data-end=\"840\"\u003e\n\u003ctr data-start=\"812\" data-end=\"840\"\u003e\n\u003cth data-start=\"812\" data-end=\"822\" data-col-size=\"sm\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-start=\"822\" data-end=\"840\" data-col-size=\"xl\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"851\" data-end=\"3128\"\u003e\n\u003ctr data-start=\"851\" data-end=\"1144\"\u003e\n\u003ctd data-start=\"851\" data-end=\"887\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"853\" data-end=\"886\"\u003e1 LDL-C and non-HDL reduction\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"887\" data-end=\"1144\" data-col-size=\"xl\"\u003eDose-dependent \u003cstrong data-start=\"904\" data-end=\"913\"\u003eLDL-C\u003c\/strong\u003e and \u003cstrong data-start=\"918\" data-end=\"934\"\u003eapoB\/non-HDL\u003c\/strong\u003e lowering via TRβ-driven \u003cstrong data-start=\"959\" data-end=\"981\"\u003eLDLR up-regulation\u003c\/strong\u003e and increased cholesterol disposal; add-on to statins shows \u003cstrong data-start=\"1042\" data-end=\"1059\"\u003ecomplementary\u003c\/strong\u003e effects. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Journal of Clinical Endocrinology \u0026amp; Metabolism; Circulation\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1145\" data-end=\"1387\"\u003e\n\u003ctd data-start=\"1145\" data-end=\"1190\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"1147\" data-end=\"1189\"\u003e2 Triglycerides \u0026amp; remnant lipoproteins\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1190\" data-end=\"1387\" data-col-size=\"xl\"\u003e\n\u003cstrong data-start=\"1192\" data-end=\"1207\"\u003eHepatic FAO\u003c\/strong\u003e and \u003cstrong data-start=\"1212\" data-end=\"1234\"\u003eVLDL output tuning\u003c\/strong\u003e reduce \u003cstrong data-start=\"1242\" data-end=\"1256\"\u003efasting TG\u003c\/strong\u003e and remnant cholesterol; small HDL-C shifts vary by dose and background therapy. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Atherosclerosis; J Lipid Research\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1388\" data-end=\"1640\"\u003e\n\u003ctd data-start=\"1388\" data-end=\"1416\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"1390\" data-end=\"1415\"\u003e3 NAFLD\/MASH activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1416\" data-end=\"1640\" data-col-size=\"xl\"\u003e\n\u003cstrong data-start=\"1418\" data-end=\"1430\"\u003eMRI-PDFF\u003c\/strong\u003e and enzyme improvements with \u003cstrong data-start=\"1460\" data-end=\"1475\"\u003esteatosis ↓\u003c\/strong\u003e; transcriptional programs favor \u003cstrong data-start=\"1508\" data-end=\"1523\"\u003eβ-oxidation\u003c\/strong\u003eand \u003cstrong data-start=\"1528\" data-end=\"1541\"\u003elipophagy\u003c\/strong\u003e, with anti-inflammatory signals downstream of TRβ. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Hepatology; Liver International\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1641\" data-end=\"1865\"\u003e\n\u003ctd data-start=\"1641\" data-end=\"1661\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"1643\" data-end=\"1660\"\u003e4 Lp(a) trend\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1661\" data-end=\"1865\" data-col-size=\"xl\"\u003eEarly clinical signals suggest \u003cstrong data-start=\"1694\" data-end=\"1719\"\u003emodest Lp(a) lowering\u003c\/strong\u003e (magnitude study-dependent); mechanism likely via \u003cstrong data-start=\"1770\" data-end=\"1808\"\u003ehepatic transcriptional remodeling\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;European Heart Journal; JAMA Cardiology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1866\" data-end=\"2114\"\u003e\n\u003ctd data-start=\"1866\" data-end=\"1910\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"1868\" data-end=\"1909\"\u003e5 Energy expenditure \u0026amp; weight signals\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1910\" data-end=\"2114\" data-col-size=\"xl\"\u003eMild \u003cstrong data-start=\"1917\" data-end=\"1949\"\u003e↑ resting energy expenditure\u003c\/strong\u003e and \u003cstrong data-start=\"1954\" data-end=\"1973\"\u003ewaist reduction\u003c\/strong\u003e in dyslipidemic\/NAFLD phenotypes without frank hyperthyroid symptoms at TRβ-selective exposures. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Cell Metabolism; Metabolism\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2115\" data-end=\"2322\"\u003e\n\u003ctd data-start=\"2115\" data-end=\"2149\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"2117\" data-end=\"2148\"\u003e6 Combination lipid therapy\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2149\" data-end=\"2322\" data-col-size=\"xl\"\u003e\n\u003cstrong data-start=\"2151\" data-end=\"2179\"\u003eAdditive LDL-C reduction\u003c\/strong\u003e with \u003cstrong data-start=\"2185\" data-end=\"2196\"\u003estatins\u003c\/strong\u003e or \u003cstrong data-start=\"2200\" data-end=\"2213\"\u003eezetimibe\u003c\/strong\u003e; potential synergy with \u003cstrong data-start=\"2238\" data-end=\"2258\"\u003ePCSK9 inhibitors\u003c\/strong\u003e for aggressive apoB lowering. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Circulation; JCEM\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2323\" data-end=\"2592\"\u003e\n\u003ctd data-start=\"2323\" data-end=\"2362\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"2325\" data-end=\"2361\"\u003e7 Atheroprotection (preclinical)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2362\" data-end=\"2592\" data-col-size=\"xl\"\u003e\n\u003cstrong data-start=\"2364\" data-end=\"2388\"\u003ePlaque cholesterol ↓\u003c\/strong\u003e, improved \u003cstrong data-start=\"2399\" data-end=\"2424\"\u003elesional inflammation\u003c\/strong\u003e and \u003cstrong data-start=\"2429\" data-end=\"2450\"\u003emacrophage efflux\u003c\/strong\u003e (ABCA1\/ABCG1) in models; outcomes trials pending. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Arteriosclerosis, Thrombosis, and Vascular Biology; Cardiovascular Research\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2593\" data-end=\"2851\"\u003e\n\u003ctd data-start=\"2593\" data-end=\"2627\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"2595\" data-end=\"2626\"\u003e8 CNS myelin\/repair biology\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2627\" data-end=\"2851\" data-col-size=\"xl\"\u003eTRβ activation promotes \u003cstrong data-start=\"2653\" data-end=\"2688\"\u003eoligodendrocyte differentiation\u003c\/strong\u003e and \u003cstrong data-start=\"2693\" data-end=\"2710\"\u003eremyelination\u003c\/strong\u003e; \u003cstrong data-start=\"2712\" data-end=\"2749\"\u003ebrain-penetrant prodrug (Sob-AM2)\u003c\/strong\u003e enhances CNS exposure and \u003cstrong data-start=\"2776\" data-end=\"2793\"\u003elowers VLCFAs\u003c\/strong\u003e in ALD models. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Brain; Annals of Neurology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2852\" data-end=\"3128\"\u003e\n\u003ctd data-start=\"2852\" data-end=\"2898\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"2854\" data-end=\"2897\"\u003e9 Very-long-chain fatty acids (ALD\/AMN)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2898\" data-end=\"3128\" data-col-size=\"xl\"\u003eSobetirome (± prodrug) \u003cstrong data-start=\"2923\" data-end=\"2947\"\u003ereduces C26:0 VLCFAs\u003c\/strong\u003e in \u003cstrong data-start=\"2951\" data-end=\"2970\"\u003eABCD1-deficient\u003c\/strong\u003e models; early human translational work is ongoing for \u003cstrong data-start=\"3025\" data-end=\"3058\"\u003eX-linked adrenoleukodystrophy\u003c\/strong\u003e phenotypes. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Science Translational Medicine; Neurology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"3130\" data-end=\"3133\"\u003e\n\u003ch2 data-start=\"3135\" data-end=\"3170\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-start=\"3172\" data-end=\"3207\"\u003e2.1 Receptor Pharmacodynamics\u003c\/h3\u003e\n\u003cul data-start=\"3208\" data-end=\"3553\"\u003e\n\u003cli data-start=\"3208\" data-end=\"3265\"\u003e\n\u003cp data-start=\"3210\" data-end=\"3265\"\u003e\u003cstrong data-start=\"3210\" data-end=\"3221\"\u003eTarget:\u003c\/strong\u003e \u003cstrong data-start=\"3222\" data-end=\"3247\"\u003eTRβ-selective agonism\u003c\/strong\u003e (liver-biased).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3266\" data-end=\"3441\"\u003e\n\u003cp data-start=\"3268\" data-end=\"3441\"\u003e\u003cstrong data-start=\"3268\" data-end=\"3288\"\u003eHepatic actions:\u003c\/strong\u003e ↑ \u003cstrong data-start=\"3291\" data-end=\"3299\"\u003eLDLR\u003c\/strong\u003e, \u003cstrong data-start=\"3301\" data-end=\"3311\"\u003eCYP7A1\u003c\/strong\u003e\/\u003cstrong data-start=\"3312\" data-end=\"3335\"\u003ebile-acid synthesis\u003c\/strong\u003e, \u003cstrong data-start=\"3337\" data-end=\"3358\"\u003eβ-oxidation genes\u003c\/strong\u003e; ↓ \u003cstrong data-start=\"3362\" data-end=\"3386\"\u003eSREBP-1c lipogenesis\u003c\/strong\u003e → \u003cstrong data-start=\"3389\" data-end=\"3410\"\u003eLDL-C\/TG lowering\u003c\/strong\u003e and \u003cstrong data-start=\"3415\" data-end=\"3438\"\u003esteatosis reduction\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3442\" data-end=\"3553\"\u003e\n\u003cp data-start=\"3444\" data-end=\"3553\"\u003e\u003cstrong data-start=\"3444\" data-end=\"3475\"\u003eCNS actions (experimental):\u003c\/strong\u003e \u003cstrong data-start=\"3476\" data-end=\"3508\"\u003eTRβ in OPCs\/oligodendrocytes\u003c\/strong\u003e → \u003cstrong data-start=\"3511\" data-end=\"3526\"\u003emyelin gene\u003c\/strong\u003e expression and maturation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"3555\" data-end=\"3582\"\u003e2.2 Down-stream Biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"3584\" data-end=\"3976\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"3584\" data-end=\"3626\"\u003e\n\u003ctr data-start=\"3584\" data-end=\"3626\"\u003e\n\u003cth data-start=\"3584\" data-end=\"3594\" data-col-size=\"sm\"\u003ePathway\u003c\/th\u003e\n\u003cth data-start=\"3594\" data-end=\"3615\" data-col-size=\"sm\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-start=\"3615\" data-end=\"3626\" data-col-size=\"sm\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"3641\" data-end=\"3976\"\u003e\n\u003ctr data-start=\"3641\" data-end=\"3736\"\u003e\n\u003ctd data-start=\"3641\" data-end=\"3679\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3643\" data-end=\"3678\"\u003eTRβ → LDLR, bile-acid synthesis\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3679\" data-end=\"3720\" data-col-size=\"sm\"\u003ePlasma LDL-C ↓, cholesterol disposal ↑\u003c\/td\u003e\n\u003ctd data-start=\"3720\" data-end=\"3736\" data-col-size=\"sm\"\u003eLiver\/lipids\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3737\" data-end=\"3804\"\u003e\n\u003ctd data-start=\"3737\" data-end=\"3773\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3739\" data-end=\"3772\"\u003ePPAR-coordinated FAO programs\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3773\" data-end=\"3795\" data-col-size=\"sm\"\u003eTG ↓, hepatic fat ↓\u003c\/td\u003e\n\u003ctd data-start=\"3795\" data-end=\"3804\" data-col-size=\"sm\"\u003eLiver\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3805\" data-end=\"3884\"\u003e\n\u003ctd data-start=\"3805\" data-end=\"3830\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3807\" data-end=\"3829\"\u003eABCA1\/ABCG1 efflux\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3830\" data-end=\"3864\" data-col-size=\"sm\"\u003eMacrophage cholesterol efflux ↑\u003c\/td\u003e\n\u003ctd data-start=\"3864\" data-end=\"3884\" data-col-size=\"sm\"\u003eAtheroprotection\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3885\" data-end=\"3976\"\u003e\n\u003ctd data-start=\"3885\" data-end=\"3927\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3887\" data-end=\"3926\"\u003eOPC differentiation genes (MBP\/MOG)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3927\" data-end=\"3951\" data-col-size=\"sm\"\u003eRemyelination support\u003c\/td\u003e\n\u003ctd data-start=\"3951\" data-end=\"3976\" data-col-size=\"sm\"\u003eCNS (prodrug-enabled)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"3978\" data-end=\"3981\"\u003e\n\u003ch2 data-start=\"3983\" data-end=\"4005\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cul data-start=\"4007\" data-end=\"4436\"\u003e\n\u003cli data-start=\"4007\" data-end=\"4053\"\u003e\n\u003cp data-start=\"4009\" data-end=\"4053\"\u003e\u003cstrong data-start=\"4009\" data-end=\"4019\"\u003eRoute:\u003c\/strong\u003e \u003cstrong data-start=\"4020\" data-end=\"4028\"\u003eOral\u003c\/strong\u003e, once-daily in trials.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4054\" data-end=\"4125\"\u003e\n\u003cp data-start=\"4056\" data-end=\"4125\"\u003e\u003cstrong data-start=\"4056\" data-end=\"4071\"\u003eAbsorption:\u003c\/strong\u003e Rapid; food effect modest (not clinically central).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4126\" data-end=\"4211\"\u003e\n\u003cp data-start=\"4128\" data-end=\"4211\"\u003e\u003cstrong data-start=\"4128\" data-end=\"4142\"\u003eHalf-life:\u003c\/strong\u003e \u003cstrong data-start=\"4143\" data-end=\"4157\"\u003eMulti-hour\u003c\/strong\u003e (supports QD dosing); hepatic distribution favored.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4212\" data-end=\"4312\"\u003e\n\u003cp data-start=\"4214\" data-end=\"4312\"\u003e\u003cstrong data-start=\"4214\" data-end=\"4239\"\u003eMetabolism\/clearance:\u003c\/strong\u003e Oxidative\/phase-II metabolism; biliary\/renal excretion of metabolites.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4313\" data-end=\"4436\"\u003e\n\u003cp data-start=\"4315\" data-end=\"4436\"\u003e\u003cstrong data-start=\"4315\" data-end=\"4336\"\u003eProdrug strategy:\u003c\/strong\u003e \u003cstrong data-start=\"4337\" data-end=\"4348\"\u003eSob-AM2\u003c\/strong\u003e increases \u003cstrong data-start=\"4359\" data-end=\"4377\"\u003ebrain exposure\u003c\/strong\u003e for CNS targets while limiting systemic thyromimetic load.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"4438\" data-end=\"4441\"\u003e\n\u003ch2 data-start=\"4443\" data-end=\"4483\"\u003e4. Pre-clinical and Clinical Evidence\u003c\/h2\u003e\n\u003ch3 data-start=\"4485\" data-end=\"4530\"\u003e4.1 Dyslipidemia \/ Mixed hyperlipidemia\u003c\/h3\u003e\n\u003cp data-start=\"4531\" data-end=\"4788\"\u003ePhase 1\/2 programs demonstrate \u003cstrong data-start=\"4562\" data-end=\"4609\"\u003eclinically relevant LDL-C and TG reductions\u003c\/strong\u003e with favorable \u003cstrong data-start=\"4625\" data-end=\"4641\"\u003eapoB\/non-HDL\u003c\/strong\u003e changes and \u003cstrong data-start=\"4654\" data-end=\"4673\"\u003eTSH suppression\u003c\/strong\u003e consistent with on-target thyroid signaling—without significant \u003cstrong data-start=\"4738\" data-end=\"4762\"\u003eTRα-like tachycardia\u003c\/strong\u003e at therapeutic exposures.\u003c\/p\u003e\n\u003ch3 data-start=\"4790\" data-end=\"4812\"\u003e4.2 NAFLD \/ MASH\u003c\/h3\u003e\n\u003cp data-start=\"4813\" data-end=\"5006\"\u003eImaging\/lab signals show \u003cstrong data-start=\"4838\" data-end=\"4863\"\u003ehepatic-fat reduction\u003c\/strong\u003e and \u003cstrong data-start=\"4868\" data-end=\"4892\"\u003eALT\/AST improvements\u003c\/strong\u003e, aligning with the hepatic TRβ mechanism. Histologic outcomes are being pursued in class programs (TRβ agonists).\u003c\/p\u003e\n\u003ch3 data-start=\"5008\" data-end=\"5044\"\u003e4.3 CNS (ALD\/MS translational)\u003c\/h3\u003e\n\u003cp data-start=\"5045\" data-end=\"5238\"\u003eSobetirome and \u003cstrong data-start=\"5060\" data-end=\"5087\"\u003ebrain-targeted prodrugs\u003c\/strong\u003e reduce \u003cstrong data-start=\"5095\" data-end=\"5105\"\u003eVLCFAs\u003c\/strong\u003e and \u003cstrong data-start=\"5110\" data-end=\"5135\"\u003eimprove remyelination\u003c\/strong\u003e indices in animals; early human translational efforts are underway (biomarkers, safety, and exposure).\u003c\/p\u003e\n\u003cblockquote data-start=\"5240\" data-end=\"5462\"\u003e\n\u003cp data-start=\"5242\" data-end=\"5462\"\u003e\u003cstrong data-start=\"5242\" data-end=\"5268\"\u003eEvidence quality note:\u003c\/strong\u003e Robust \u003cstrong data-start=\"5276\" data-end=\"5291\"\u003emechanistic\u003c\/strong\u003e and \u003cstrong data-start=\"5296\" data-end=\"5311\"\u003epreclinical\u003c\/strong\u003e data; \u003cstrong data-start=\"5318\" data-end=\"5339\"\u003eearly-phase human\u003c\/strong\u003e trials show lipid\/steatosis signals. Hard outcomes (CV events, MASH histology, neurologic disability) remain \u003cstrong data-start=\"5449\" data-end=\"5461\"\u003eunproven\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003chr data-start=\"5464\" data-end=\"5467\"\u003e\n\u003ch2 data-start=\"5469\" data-end=\"5502\"\u003e5. Emerging Clinical Interests\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"5504\" data-end=\"6070\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"5504\" data-end=\"5534\"\u003e\n\u003ctr data-start=\"5504\" data-end=\"5534\"\u003e\n\u003cth data-start=\"5504\" data-end=\"5512\" data-col-size=\"sm\"\u003eField\u003c\/th\u003e\n\u003cth data-start=\"5512\" data-end=\"5524\" data-col-size=\"md\"\u003eRationale\u003c\/th\u003e\n\u003cth data-start=\"5524\" data-end=\"5534\" data-col-size=\"sm\"\u003eStatus\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"5549\" data-end=\"6070\"\u003e\n\u003ctr data-start=\"5549\" data-end=\"5638\"\u003e\n\u003ctd data-start=\"5549\" data-end=\"5580\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5551\" data-end=\"5579\"\u003eApoB-driven dyslipidemia\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5580\" data-end=\"5613\" data-col-size=\"md\"\u003eHepatic TRβ LDLR up-regulation\u003c\/td\u003e\n\u003ctd data-start=\"5613\" data-end=\"5638\" data-col-size=\"sm\"\u003ePhase 2–style signals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5639\" data-end=\"5727\"\u003e\n\u003ctd data-start=\"5639\" data-end=\"5672\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5641\" data-end=\"5671\"\u003eStatin-intolerant \/ add-on\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5672\" data-end=\"5708\" data-col-size=\"md\"\u003eNon-myotoxic mechanism, stackable\u003c\/td\u003e\n\u003ctd data-start=\"5708\" data-end=\"5727\" data-col-size=\"sm\"\u003eInvestigational\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5728\" data-end=\"5781\"\u003e\n\u003ctd data-start=\"5728\" data-end=\"5745\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5730\" data-end=\"5744\"\u003eNAFLD\/MASH\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5745\" data-end=\"5770\" data-col-size=\"md\"\u003eSteatosis ↓, enzymes ↓\u003c\/td\u003e\n\u003ctd data-start=\"5770\" data-end=\"5781\" data-col-size=\"sm\"\u003eOngoing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5782\" data-end=\"5890\"\u003e\n\u003ctd data-start=\"5782\" data-end=\"5828\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5784\" data-end=\"5827\"\u003eFamilial hypercholesterolemia (adjunct)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5828\" data-end=\"5875\" data-col-size=\"md\"\u003eAdditional LDL-C lowering with PCSK9\/statins\u003c\/td\u003e\n\u003ctd data-start=\"5875\" data-end=\"5890\" data-col-size=\"sm\"\u003eExploratory\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5891\" data-end=\"5961\"\u003e\n\u003ctd data-start=\"5891\" data-end=\"5914\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5893\" data-end=\"5913\"\u003eX-linked ALD\/AMN\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5914\" data-end=\"5944\" data-col-size=\"md\"\u003eVLCFA lowering; CNS prodrug\u003c\/td\u003e\n\u003ctd data-start=\"5944\" data-end=\"5961\" data-col-size=\"sm\"\u003eTranslational\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5962\" data-end=\"6070\"\u003e\n\u003ctd data-start=\"5962\" data-end=\"5995\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5964\" data-end=\"5994\"\u003eMS remyelination (concept)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5995\" data-end=\"6035\" data-col-size=\"md\"\u003eTRβ-driven oligodendrocyte maturation\u003c\/td\u003e\n\u003ctd data-start=\"6035\" data-end=\"6070\" data-col-size=\"sm\"\u003ePreclinical\/early translational\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"6072\" data-end=\"6075\"\u003e\n\u003ch2 data-start=\"6077\" data-end=\"6106\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cul data-start=\"6108\" data-end=\"6998\"\u003e\n\u003cli data-start=\"6108\" data-end=\"6298\"\u003e\n\u003cp data-start=\"6110\" data-end=\"6298\"\u003e\u003cstrong data-start=\"6110\" data-end=\"6138\"\u003eClass\/on-target effects:\u003c\/strong\u003e \u003cstrong data-start=\"6139\" data-end=\"6158\"\u003eTSH suppression\u003c\/strong\u003e, \u003cstrong data-start=\"6160\" data-end=\"6181\"\u003eT3\/T4 axis shifts\u003c\/strong\u003e (generally mild); \u003cstrong data-start=\"6200\" data-end=\"6214\"\u003eheart-rate\u003c\/strong\u003e\/palpitations uncommon at TRβ-selective exposures but possible with over-exposure.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6299\" data-end=\"6423\"\u003e\n\u003cp data-start=\"6301\" data-end=\"6423\"\u003e\u003cstrong data-start=\"6301\" data-end=\"6316\"\u003eCommon AEs:\u003c\/strong\u003e \u003cstrong data-start=\"6317\" data-end=\"6329\"\u003eHeadache\u003c\/strong\u003e, \u003cstrong data-start=\"6331\" data-end=\"6343\"\u003eGI upset\u003c\/strong\u003e, \u003cstrong data-start=\"6345\" data-end=\"6362\"\u003emild insomnia\u003c\/strong\u003e, \u003cstrong data-start=\"6364\" data-end=\"6380\"\u003ewarmth\/flush\u003c\/strong\u003e, \u003cstrong data-start=\"6382\" data-end=\"6404\"\u003etransaminase drift\u003c\/strong\u003e (usually small).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6424\" data-end=\"6566\"\u003e\n\u003cp data-start=\"6426\" data-end=\"6566\"\u003e\u003cstrong data-start=\"6426\" data-end=\"6443\"\u003eCardiac\/bone:\u003c\/strong\u003e Designed to spare \u003cstrong data-start=\"6462\" data-end=\"6469\"\u003eTRα\u003c\/strong\u003e; nonetheless, monitor \u003cstrong data-start=\"6492\" data-end=\"6501\"\u003eHR\/BP\u003c\/strong\u003e and \u003cstrong data-start=\"6506\" data-end=\"6531\"\u003ebone-turnover markers\u003c\/strong\u003e with prolonged use or high dose.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6567\" data-end=\"6643\"\u003e\n\u003cp data-start=\"6569\" data-end=\"6643\"\u003e\u003cstrong data-start=\"6569\" data-end=\"6581\"\u003eHepatic:\u003c\/strong\u003e Periodic \u003cstrong data-start=\"6591\" data-end=\"6602\"\u003eALT\/AST\u003c\/strong\u003e monitoring—particularly in NAFLD\/MASH.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6644\" data-end=\"6754\"\u003e\n\u003cp data-start=\"6646\" data-end=\"6754\"\u003e\u003cstrong data-start=\"6646\" data-end=\"6660\"\u003eEndocrine:\u003c\/strong\u003e Avoid in \u003cstrong data-start=\"6670\" data-end=\"6699\"\u003euntreated hyperthyroidism\u003c\/strong\u003e; use caution with \u003cstrong data-start=\"6718\" data-end=\"6732\"\u003eamiodarone\u003c\/strong\u003e or \u003cstrong data-start=\"6736\" data-end=\"6751\"\u003eiodine load\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6755\" data-end=\"6808\"\u003e\n\u003cp data-start=\"6757\" data-end=\"6808\"\u003e\u003cstrong data-start=\"6757\" data-end=\"6771\"\u003ePregnancy:\u003c\/strong\u003e Avoid (thyroid-axis manipulation).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6809\" data-end=\"6998\"\u003e\n\u003cp data-start=\"6811\" data-end=\"6998\"\u003e\u003cstrong data-start=\"6811\" data-end=\"6833\"\u003eDrug interactions:\u003c\/strong\u003e Potential with \u003cstrong data-start=\"6849\" data-end=\"6874\"\u003ewarfarin (INR shifts)\u003c\/strong\u003e, \u003cstrong data-start=\"6876\" data-end=\"6903\"\u003eCYP inducers\/inhibitors\u003c\/strong\u003e, and agents affecting \u003cstrong data-start=\"6926\" data-end=\"6955\"\u003ethyroid binding\/transport\u003c\/strong\u003e; separate from \u003cstrong data-start=\"6971\" data-end=\"6997\"\u003ebile-acid sequestrants\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"7000\" data-end=\"7045\"\u003e\u003cstrong data-start=\"7000\" data-end=\"7045\"\u003eComparative safety matrix (thyromimetics)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"7047\" data-end=\"7528\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"7047\" data-end=\"7112\"\u003e\n\u003ctr data-start=\"7047\" data-end=\"7112\"\u003e\n\u003cth data-start=\"7047\" data-end=\"7057\" data-col-size=\"sm\"\u003eFeature\u003c\/th\u003e\n\u003cth data-start=\"7057\" data-end=\"7081\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7059\" data-end=\"7080\"\u003eSobetirome (GC-1)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"7081\" data-end=\"7098\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7083\" data-end=\"7097\"\u003eEprotirome\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"7098\" data-end=\"7112\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7100\" data-end=\"7110\"\u003eVK2809\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"7131\" data-end=\"7528\"\u003e\n\u003ctr data-start=\"7131\" data-end=\"7232\"\u003e\n\u003ctd data-start=\"7131\" data-end=\"7154\" data-col-size=\"sm\"\u003eReceptor selectivity\u003c\/td\u003e\n\u003ctd data-start=\"7154\" data-end=\"7174\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7156\" data-end=\"7173\"\u003eTRβ-selective\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"7174\" data-end=\"7190\" data-col-size=\"sm\"\u003eTRβ-selective\u003c\/td\u003e\n\u003ctd data-start=\"7190\" data-end=\"7232\" data-col-size=\"sm\"\u003eTRβ-selective (liver-targeted prodrug)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7233\" data-end=\"7289\"\u003e\n\u003ctd data-start=\"7233\" data-end=\"7241\" data-col-size=\"sm\"\u003eRoute\u003c\/td\u003e\n\u003ctd data-start=\"7241\" data-end=\"7252\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7243\" data-end=\"7251\"\u003eOral\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"7252\" data-end=\"7259\" data-col-size=\"sm\"\u003eOral\u003c\/td\u003e\n\u003ctd data-start=\"7259\" data-end=\"7289\" data-col-size=\"sm\"\u003eOral (hepatocyte-targeted)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7290\" data-end=\"7407\"\u003e\n\u003ctd data-start=\"7290\" data-end=\"7307\" data-col-size=\"sm\"\u003eLDL\/TG effects\u003c\/td\u003e\n\u003ctd data-start=\"7307\" data-end=\"7337\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7309\" data-end=\"7336\"\u003eRobust (dose-dependent)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"7337\" data-end=\"7379\" data-col-size=\"sm\"\u003eRobust (program halted for tox in dogs)\u003c\/td\u003e\n\u003ctd data-start=\"7379\" data-end=\"7407\" data-col-size=\"sm\"\u003eRobust (Phase 2 signals)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7408\" data-end=\"7528\"\u003e\n\u003ctd data-start=\"7408\" data-end=\"7423\" data-col-size=\"sm\"\u003eKey concerns\u003c\/td\u003e\n\u003ctd data-start=\"7423\" data-end=\"7464\" data-col-size=\"sm\"\u003eAxis suppression (manageable), mild HR\u003c\/td\u003e\n\u003ctd data-start=\"7464\" data-end=\"7492\" data-col-size=\"sm\"\u003ePreclinical cartilage tox\u003c\/td\u003e\n\u003ctd data-start=\"7492\" data-end=\"7528\" data-col-size=\"sm\"\u003eAxis suppression, LFTs (monitor)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"7530\" data-end=\"7533\"\u003e\n\u003ch2 data-start=\"7535\" data-end=\"7561\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-start=\"7563\" data-end=\"7841\"\u003e\n\u003cli data-start=\"7563\" data-end=\"7603\"\u003e\n\u003cp data-start=\"7565\" data-end=\"7603\"\u003e\u003cstrong data-start=\"7565\" data-end=\"7581\"\u003eNot approved\u003c\/strong\u003e for any indication.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7604\" data-end=\"7747\"\u003e\n\u003cp data-start=\"7606\" data-end=\"7747\"\u003eBeing developed for \u003cstrong data-start=\"7626\" data-end=\"7648\"\u003edyslipidemia\/NAFLD\u003c\/strong\u003e (adjunct to standard of care) and \u003cstrong data-start=\"7683\" data-end=\"7702\"\u003erare neurologic\u003c\/strong\u003e indications via \u003cstrong data-start=\"7719\" data-end=\"7744\"\u003eCNS-targeted prodrugs\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7748\" data-end=\"7841\"\u003e\n\u003cp data-start=\"7750\" data-end=\"7841\"\u003eNo sport relevance (not a performance drug), but \u003cstrong data-start=\"7799\" data-end=\"7840\"\u003eoff-label\/compound use is not advised\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"7843\" data-end=\"7846\"\u003e\n\u003ch2 data-start=\"7848\" data-end=\"7871\"\u003e8. Future Directions\u003c\/h2\u003e\n\u003cul data-start=\"7873\" data-end=\"8554\"\u003e\n\u003cli data-start=\"7873\" data-end=\"8021\"\u003e\n\u003cp data-start=\"7875\" data-end=\"8021\"\u003e\u003cstrong data-start=\"7875\" data-end=\"7904\"\u003eCardiometabolic outcomes:\u003c\/strong\u003e ApoB-anchored Phase 3 with \u003cstrong data-start=\"7932\" data-end=\"7940\"\u003eMACE\u003c\/strong\u003e endpoints; combination strategies with \u003cstrong data-start=\"7980\" data-end=\"8018\"\u003estatins, ezetimibe, PCSK9, ANGPTL3\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8022\" data-end=\"8136\"\u003e\n\u003cp data-start=\"8024\" data-end=\"8136\"\u003e\u003cstrong data-start=\"8024\" data-end=\"8043\"\u003eMASH histology:\u003c\/strong\u003e Biopsy-based trials (NASH resolution, fibrosis endpoints) and \u003cstrong data-start=\"8106\" data-end=\"8122\"\u003eMRI-PDFF\/MRE\u003c\/strong\u003e composites.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8137\" data-end=\"8261\"\u003e\n\u003cp data-start=\"8139\" data-end=\"8261\"\u003e\u003cstrong data-start=\"8139\" data-end=\"8164\"\u003eDose-exposure models:\u003c\/strong\u003e Define \u003cstrong data-start=\"8172\" data-end=\"8199\"\u003eTRβ selectivity windows\u003c\/strong\u003e that preserve axis efficacy with minimal \u003cstrong data-start=\"8241\" data-end=\"8248\"\u003eTRα\u003c\/strong\u003e spillover.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8262\" data-end=\"8433\"\u003e\n\u003cp data-start=\"8264\" data-end=\"8433\"\u003e\u003cstrong data-start=\"8264\" data-end=\"8281\"\u003eCNS programs:\u003c\/strong\u003e Optimize \u003cstrong data-start=\"8291\" data-end=\"8302\"\u003eSob-AM2\u003c\/strong\u003e or next-gen brain-penetrant analogs; \u003cstrong data-start=\"8340\" data-end=\"8349\"\u003eVLCFA\u003c\/strong\u003e, \u003cstrong data-start=\"8351\" data-end=\"8375\"\u003emyelin imaging (MTR)\u003c\/strong\u003e, and \u003cstrong data-start=\"8381\" data-end=\"8404\"\u003efunctional outcomes\u003c\/strong\u003e in \u003cstrong data-start=\"8408\" data-end=\"8419\"\u003eALD\/AMN\u003c\/strong\u003e and \u003cstrong data-start=\"8424\" data-end=\"8430\"\u003eMS\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8434\" data-end=\"8554\"\u003e\n\u003cp data-start=\"8436\" data-end=\"8554\"\u003e\u003cstrong data-start=\"8436\" data-end=\"8458\"\u003eSafety registries:\u003c\/strong\u003e Long-term \u003cstrong data-start=\"8469\" data-end=\"8485\"\u003ethyroid axis\u003c\/strong\u003e, \u003cstrong data-start=\"8487\" data-end=\"8505\"\u003ecardiac rhythm\u003c\/strong\u003e, \u003cstrong data-start=\"8507\" data-end=\"8523\"\u003ebone density\u003c\/strong\u003e, and \u003cstrong data-start=\"8529\" data-end=\"8540\"\u003ehepatic\u003c\/strong\u003e surveillance.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"8556\" data-end=\"8559\"\u003e\n\u003ch3 data-start=\"8561\" data-end=\"8584\"\u003eSelected References\u003c\/h3\u003e\n\u003cul data-start=\"8586\" data-end=\"9480\"\u003e\n\u003cli data-start=\"8586\" data-end=\"8741\"\u003e\n\u003cp data-start=\"8588\" data-end=\"8741\"\u003e\u003cstrong data-start=\"8588\" data-end=\"8647\"\u003eCirculation; Atherosclerosis; Journal of Lipid Research\u003c\/strong\u003e — TRβ agonism, LDLR up-regulation, and lipoprotein remodeling with sobetirome-class agents.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8742\" data-end=\"8843\"\u003e\n\u003cp data-start=\"8744\" data-end=\"8843\"\u003e\u003cstrong data-start=\"8744\" data-end=\"8779\"\u003eHepatology; Liver International\u003c\/strong\u003e — TRβ-driven steatosis reduction and NAFLD biomarker changes.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8844\" data-end=\"8953\"\u003e\n\u003cp data-start=\"8846\" data-end=\"8953\"\u003e\u003cstrong data-start=\"8846\" data-end=\"8896\"\u003eJournal of Clinical Endocrinology \u0026amp; Metabolism\u003c\/strong\u003e — Early human lipid\/thyroid-axis data with sobetirome.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8954\" data-end=\"9104\"\u003e\n\u003cp data-start=\"8956\" data-end=\"9104\"\u003e\u003cstrong data-start=\"8956\" data-end=\"9035\"\u003eArteriosclerosis, Thrombosis, and Vascular Biology; Cardiovascular Research\u003c\/strong\u003e — Atheroprotection mechanisms (macrophage efflux, plaque biology).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9105\" data-end=\"9204\"\u003e\n\u003cp data-start=\"9107\" data-end=\"9204\"\u003e\u003cstrong data-start=\"9107\" data-end=\"9137\"\u003eBrain; Annals of Neurology\u003c\/strong\u003e — TRβ in oligodendrocyte maturation and remyelination paradigms.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9205\" data-end=\"9354\"\u003e\n\u003cp data-start=\"9207\" data-end=\"9354\"\u003e\u003cstrong data-start=\"9207\" data-end=\"9252\"\u003eScience Translational Medicine; Neurology\u003c\/strong\u003e — Sobetirome\/Sob-AM2 lowering VLCFAs in \u003cstrong data-start=\"9293\" data-end=\"9302\"\u003eABCD1\u003c\/strong\u003e models and translational steps for \u003cstrong data-start=\"9338\" data-end=\"9351\"\u003eX-ALD\/AMN\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9355\" data-end=\"9480\"\u003e\n\u003cp data-start=\"9357\" data-end=\"9480\"\u003e\u003cstrong data-start=\"9357\" data-end=\"9388\"\u003eCell Metabolism; Metabolism\u003c\/strong\u003e — Energy-expenditure and hepatic transcriptional programs under thyroid hormone mimetics.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"6654\" data-start=\"6575\"\u003e \u003c\/p\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684858720594,"sku":null,"price":120.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/sobetirome_10000mcg.png?v=1770834892"},{"product_id":"lipo-c-10mg-vial","title":"Lipo-c 10mg vial","description":"\u003cp data-start=\"345\" data-end=\"813\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                              \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN \u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eCONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-start=\"345\" data-end=\"813\"\u003e\u003cstrong data-start=\"345\" data-end=\"366\"\u003eLipo-C\u003c\/strong\u003e, commonly referred to as \u003cstrong data-start=\"392\" data-end=\"410\"\u003eMIC injections\u003c\/strong\u003e (denoting Methionine, Inositol, and Choline), are a blend of lipotropic compounds and essential nutrients designed to enhance fat metabolism and support weight management. These injections are often utilized as adjuncts in weight loss programs, aiming to facilitate the breakdown and elimination of fat, boost energy levels, and improve overall metabolic function.\u003c\/p\u003e\n\u003chr data-start=\"815\" data-end=\"818\"\u003e\n\u003ch2 data-start=\"820\" data-end=\"865\"\u003e\u003cstrong data-start=\"823\" data-end=\"865\"\u003e2. Composition and Mechanism of Action\u003c\/strong\u003e\u003c\/h2\u003e\n\u003ch3 data-start=\"867\" data-end=\"894\"\u003e\u003cstrong data-start=\"871\" data-end=\"894\"\u003e2.1. Key Components\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cul data-start=\"896\" data-end=\"2148\"\u003e\n\u003cli data-start=\"896\" data-end=\"1129\"\u003e\n\u003cp data-start=\"898\" data-end=\"1129\"\u003e\u003cstrong data-start=\"898\" data-end=\"912\"\u003eMethionine\u003c\/strong\u003e: An essential amino acid that aids in the breakdown of fats and helps prevent the accumulation of fat in the liver. It also assists in detoxifying harmful substances in the body.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1131\" data-end=\"1355\"\u003e\n\u003cp data-start=\"1133\" data-end=\"1355\"\u003e\u003cstrong data-start=\"1133\" data-end=\"1145\"\u003eInositol\u003c\/strong\u003e: Aids in the metabolism of fats and helps reduce blood cholesterol. It also participates in the action of serotonin, a neurotransmitter known to control mood and appetite.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1357\" data-end=\"1591\"\u003e\n\u003cp data-start=\"1359\" data-end=\"1591\"\u003e\u003cstrong data-start=\"1359\" data-end=\"1370\"\u003eCholine\u003c\/strong\u003e: Supports the health of the liver in its processing and excretion of chemical waste products. It is required for the transport and metabolism of fats and cholesterol within the body.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1593\" data-end=\"1808\"\u003e\n\u003cp data-start=\"1595\" data-end=\"1808\"\u003e\u003cstrong data-start=\"1595\" data-end=\"1622\"\u003eVitamin B12 (Cobalamin)\u003c\/strong\u003e: Plays a vital role in maintaining the health of nerve cells and red blood cells. It is also needed to make DNA, the genetic material in all cells.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1810\" data-end=\"1982\"\u003e\n\u003cp data-start=\"1812\" data-end=\"1982\"\u003e\u003cstrong data-start=\"1812\" data-end=\"1827\"\u003eL-Carnitine\u003c\/strong\u003e: Facilitates the transport of fatty acids into the mitochondria of cells, where they are oxidized to produce energy.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1984\" data-end=\"2148\"\u003e\n\u003cp data-start=\"1986\" data-end=\"2148\"\u003e\u003cstrong data-start=\"1986\" data-end=\"2037\"\u003eVitamin B1 (Thiamine) and B5 (Pantothenic Acid)\u003c\/strong\u003e: Essential for energy metabolism and the synthesis of neurotransmitters.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"2150\" data-end=\"2182\"\u003e\u003cstrong data-start=\"2154\" data-end=\"2182\"\u003e2.2. Mechanism of Action\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp data-start=\"2184\" data-end=\"2242\"\u003eThe synergistic effect of these components is believed to:\u003c\/p\u003e\n\u003cul data-start=\"2244\" data-end=\"2544\"\u003e\n\u003cli data-start=\"2244\" data-end=\"2304\"\u003e\n\u003cp data-start=\"2246\" data-end=\"2304\"\u003eEnhance the liver's ability to process and eliminate fats.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2305\" data-end=\"2375\"\u003e\n\u003cp data-start=\"2307\" data-end=\"2375\"\u003eIncrease the body's metabolic rate, leading to more calories burned.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2376\" data-end=\"2440\"\u003e\n\u003cp data-start=\"2378\" data-end=\"2440\"\u003eBoost energy levels, facilitating increased physical activity.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2441\" data-end=\"2544\"\u003e\n\u003cp data-start=\"2443\" data-end=\"2544\"\u003eSupport the maintenance of lean muscle mass during weight loss.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"2546\" data-end=\"2549\"\u003e\n\u003ch2 data-start=\"2551\" data-end=\"2578\"\u003e\u003cstrong data-start=\"2554\" data-end=\"2578\"\u003e3. Clinical Efficacy\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp data-start=\"2580\" data-end=\"2720\"\u003eWhile anecdotal reports and some clinical practices suggest benefits of Lipo-C injections in weight management, it's important to note that:\u003c\/p\u003e\n\u003cul data-start=\"2722\" data-end=\"3433\"\u003e\n\u003cli data-start=\"2722\" data-end=\"2961\"\u003e\n\u003cp data-start=\"2724\" data-end=\"2961\"\u003e\u003cstrong data-start=\"2724\" data-end=\"2747\"\u003eScientific Evidence\u003c\/strong\u003e: There is limited peer-reviewed research specifically evaluating the efficacy of Lipo-C injections for weight loss. Most evidence is anecdotal or based on small-scale studies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2963\" data-end=\"3189\"\u003e\n\u003cp data-start=\"2965\" data-end=\"3189\"\u003e\u003cstrong data-start=\"2965\" data-end=\"2984\"\u003eAdjunctive Role\u003c\/strong\u003e: Lipo-C injections are typically used in conjunction with calorie-restricted diets and exercise programs, making it challenging to isolate their individual effects.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3191\" data-end=\"3433\"\u003e\n\u003cp data-start=\"3193\" data-end=\"3433\"\u003e\u003cstrong data-start=\"3193\" data-end=\"3219\"\u003eIndividual Variability\u003c\/strong\u003e: Responses to Lipo-C injections can vary widely among individuals, influenced by factors such as baseline metabolic rate, diet, exercise habits, and genetic predispositions.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"3435\" data-end=\"3438\"\u003e\n\u003ch2 data-start=\"3440\" data-end=\"3473\"\u003e\u003cstrong data-start=\"3443\" data-end=\"3473\"\u003e4. Safety and Tolerability\u003c\/strong\u003e\u003c\/h2\u003e\n\u003ch3 data-start=\"3475\" data-end=\"3507\"\u003e\u003cstrong data-start=\"3479\" data-end=\"3507\"\u003e4.1. Common Side Effects\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cul data-start=\"3509\" data-end=\"3664\"\u003e\n\u003cli data-start=\"3509\" data-end=\"3557\"\u003e\n\u003cp data-start=\"3511\" data-end=\"3557\"\u003eMild discomfort or pain at the injection site.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3558\" data-end=\"3593\"\u003e\n\u003cp data-start=\"3560\" data-end=\"3593\"\u003eNausea or gastrointestinal upset.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3594\" data-end=\"3664\"\u003e\n\u003cp data-start=\"3596\" data-end=\"3664\"\u003eHeadache or lightheadedness.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"3666\" data-end=\"3708\"\u003e\u003cstrong data-start=\"3670\" data-end=\"3708\"\u003e4.2. Rare but Serious Side Effects\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cul data-start=\"3710\" data-end=\"3846\"\u003e\n\u003cli data-start=\"3710\" data-end=\"3769\"\u003e\n\u003cp data-start=\"3712\" data-end=\"3769\"\u003eAllergic reactions, including rash, itching, or swelling.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3770\" data-end=\"3846\"\u003e\n\u003cp data-start=\"3772\" data-end=\"3846\"\u003eDizziness or difficulty breathing.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"3848\" data-end=\"3894\"\u003e\u003cstrong data-start=\"3852\" data-end=\"3894\"\u003e4.3. Contraindications and Precautions\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cul data-start=\"3896\" data-end=\"4145\"\u003e\n\u003cli data-start=\"3896\" data-end=\"3960\"\u003e\n\u003cp data-start=\"3898\" data-end=\"3960\"\u003eIndividuals with allergies to any components of the injection.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3961\" data-end=\"4042\"\u003e\n\u003cp data-start=\"3963\" data-end=\"4042\"\u003ePregnant or breastfeeding women should consult healthcare providers before use.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4043\" data-end=\"4145\"\u003e\n\u003cp data-start=\"4045\" data-end=\"4145\"\u003ePatients with liver or kidney conditions should use caution.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"4147\" data-end=\"4150\"\u003e\n\u003ch2 data-start=\"4152\" data-end=\"4187\"\u003e\u003cstrong data-start=\"4155\" data-end=\"4187\"\u003e5. Administration and Dosage\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cul data-start=\"4189\" data-end=\"4597\"\u003e\n\u003cli data-start=\"4189\" data-end=\"4280\"\u003e\n\u003cp data-start=\"4191\" data-end=\"4280\"\u003e\u003cstrong data-start=\"4191\" data-end=\"4200\"\u003eRoute\u003c\/strong\u003e: Intramuscular injection, commonly administered in the arm, thigh, or buttocks.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4282\" data-end=\"4396\"\u003e\n\u003cp data-start=\"4284\" data-end=\"4396\"\u003e\u003cstrong data-start=\"4284\" data-end=\"4297\"\u003eFrequency\u003c\/strong\u003e: Varies based on individual needs and clinical protocols; often administered once or twice weekly.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4398\" data-end=\"4597\"\u003e\n\u003cp data-start=\"4400\" data-end=\"4597\"\u003e\u003cstrong data-start=\"4400\" data-end=\"4410\"\u003eDosage\u003c\/strong\u003e: Specific dosages depend on the formulation and clinical judgment; standardized dosing guidelines are lacking due to limited regulatory oversight.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"4599\" data-end=\"4602\"\u003e\n\u003ch2 data-start=\"4604\" data-end=\"4631\"\u003e\u003cstrong data-start=\"4607\" data-end=\"4631\"\u003e6. Regulatory Status\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cul data-start=\"4633\" data-end=\"5133\"\u003e\n\u003cli data-start=\"4633\" data-end=\"4937\"\u003e\n\u003cp data-start=\"4635\" data-end=\"4937\"\u003e\u003cstrong data-start=\"4635\" data-end=\"4651\"\u003eFDA Approval\u003c\/strong\u003e: Lipo-C injections, as compounded formulations, are not specifically approved by the U.S. Food and Drug Administration (FDA). However, the individual components (e.g., methionine, inositol, choline, vitamin B12) are generally recognized as safe.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4939\" data-end=\"5133\"\u003e\n\u003cp data-start=\"4941\" data-end=\"5133\"\u003e\u003cstrong data-start=\"4941\" data-end=\"4960\"\u003eQuality Control\u003c\/strong\u003e: The lack of FDA approval for the compounded product underscores the importance of obtaining these injections from reputable medical providers to ensure quality and safety.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"5135\" data-end=\"5138\"\u003e\n\u003ch2 data-start=\"5140\" data-end=\"5160\"\u003e\u003cstrong data-start=\"5143\" data-end=\"5160\"\u003e7. Conclusion\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp data-start=\"5162\" data-end=\"5670\"\u003eLipo-C injections comprise a combination of lipotropic agents and essential nutrients aimed at supporting fat metabolism and energy production. While they are widely used in clinical practice as adjuncts to weight loss programs, robust scientific evidence supporting their standalone efficacy is limited. Individuals considering Lipo-C injections should do so under the guidance of qualified healthcare professionals and in conjunction with comprehensive lifestyle modifications, including diet and exercise.\u003c\/p\u003e\n\u003chr data-start=\"5672\" data-end=\"5675\"\u003e\n\u003cp data-start=\"5677\" data-end=\"5692\"\u003e\u003cstrong data-start=\"5677\" data-end=\"5692\"\u003eReferences:\u003c\/strong\u003e\u003c\/p\u003e\n\u003col data-start=\"5694\" data-end=\"6500\"\u003e\n\u003cli data-start=\"5694\" data-end=\"5877\"\u003e\n\u003cp data-start=\"5697\" data-end=\"5877\"\u003eEmpower Pharmacy. Lipo-C Injection. \u003ca data-start=\"5733\" data-end=\"5877\" class=\"cursor-pointer\" rel=\"noopener\"\u003ehttps:\/\/www.empowerpharmacy.com\/compounding-pharmacy\/lipo-c-injection\/\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5878\" data-end=\"6072\"\u003e\n\u003cp data-start=\"5881\" data-end=\"6072\"\u003eHealthline. Lipotropic Injections: Benefits, Side Effects, Dosage, and Cost. \u003ca data-start=\"5958\" data-end=\"6072\" class=\"cursor-pointer\" rel=\"noopener\"\u003ehttps:\/\/www.healthline.com\/health\/lipotropic-injections\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6073\" data-end=\"6215\"\u003e\n\u003cp data-start=\"6076\" data-end=\"6215\"\u003eDefy Medical. What is in Lipo-C? \u003ca data-start=\"6109\" data-end=\"6215\" class=\"cursor-pointer\" rel=\"noopener\"\u003ehttps:\/\/www.defymedical.com\/blog\/what-is-in-lipo-c\/\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6216\" data-end=\"6500\"\u003e\n\u003cp data-start=\"6219\" data-end=\"6500\"\u003eHydraMed. The Ultimate Guide to Lipo C Injections: Benefits, Side Effects, and More. \u003ca class=\"cursor-pointer\" rel=\"noopener\" data-start=\"6304\" data-end=\"6500\"\u003ehttps:\/\/hydramed.com\/blog\/the-ultimate-guide-to-lipo-c-injections-benefits-side-effects-and-more\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684859015506,"sku":null,"price":75.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/LIPO-c_10mg.png?v=1770834896"},{"product_id":"mazdutide-10mg-vial","title":"Mazdutide 10mg vial","description":"\u003cp class=\"\" data-end=\"426\" data-start=\"272\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                            \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN \u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eCONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"\" data-end=\"426\" data-start=\"272\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003e\u003cstrong data-is-only-node=\"\" data-end=\"13\" data-start=\"0\"\u003eMazdutide\u003c\/strong\u003e is an investigational, once-weekly injectable peptide developed collaboratively by Innovent Biologics and Eli Lilly.\u003c\/span\u003e \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eIt functions as a dual agonist of the \u003cstrong data-end=\"83\" data-start=\"38\"\u003eglucagon-like peptide-1 receptor (GLP-1R)\u003c\/strong\u003e and the \u003cstrong data-end=\"120\" data-start=\"92\"\u003eglucagon receptor (GCGR)\u003c\/strong\u003e.\u003c\/span\u003e \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eThis dual mechanism aims to synergistically enhance glycemic control and promote weight loss, positioning mazdutide as a promising therapeutic candidate for \u003cstrong data-end=\"168\" data-start=\"157\"\u003eobesity\u003c\/strong\u003e and \u003cstrong data-end=\"208\" data-start=\"173\"\u003etype 2 diabetes mellitus (T2DM)\u003c\/strong\u003e.\u003c\/span\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr class=\"\" data-end=\"431\" data-start=\"428\"\u003e\n\u003ch2 class=\"\" data-end=\"462\" data-start=\"433\"\u003e\u003cstrong data-end=\"462\" data-start=\"436\"\u003e2. Mechanism of Action\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"542\" data-start=\"464\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eMazdutide's dual agonism of GLP-1R and GCGR facilitates multiple metabolic benefits:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul data-end=\"750\" data-start=\"544\"\u003e\n\u003cli class=\"\" data-end=\"647\" data-start=\"544\"\u003e\n\u003cp class=\"\" data-end=\"647\" data-start=\"546\"\u003e\u003cstrong data-end=\"567\" data-start=\"546\"\u003eGLP-1R Activation\u003c\/strong\u003e: \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eEnhances glucose-dependent insulin secretion, suppresses glucagon release, delays gastric emptying, and promotes satiety.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"750\" data-start=\"649\"\u003e\n\u003cp class=\"\" data-end=\"750\" data-start=\"651\"\u003e\u003cstrong data-end=\"670\" data-start=\"651\"\u003eGCGR Activation\u003c\/strong\u003e: \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eIncreases energy expenditure and promotes lipolysis, contributing to weight reduction.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"\" data-end=\"830\" data-start=\"752\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eBy concurrently targeting these receptors, mazdutide aims to achieve superior metabolic outcomes compared to agents that activate GLP-1R alone.\u003c\/span\u003e\u003c\/p\u003e\n\u003chr class=\"\" data-end=\"835\" data-start=\"832\"\u003e\n\u003ch2 class=\"\" data-end=\"864\" data-start=\"837\"\u003e\u003cstrong data-end=\"864\" data-start=\"840\"\u003e3. Clinical Efficacy\u003c\/strong\u003e\u003c\/h2\u003e\n\u003ch3 class=\"\" data-end=\"923\" data-start=\"866\"\u003e\u003cstrong data-end=\"923\" data-start=\"870\"\u003e3.1. Phase 2 Trial in Overweight and Obese Adults\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"\" data-end=\"1043\" data-start=\"925\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eA randomized, double-blind, placebo-controlled Phase 2 trial evaluated mazdutide's efficacy over 24 weeks in Chinese adults with overweight or obesity.\u003c\/span\u003e \u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cul data-end=\"1374\" data-start=\"1045\"\u003e\n\u003cli class=\"\" data-end=\"1143\" data-start=\"1045\"\u003e\n\u003cp class=\"\" data-end=\"1143\" data-start=\"1047\"\u003e\u003cstrong data-end=\"1063\" data-start=\"1047\"\u003eParticipants\u003c\/strong\u003e: \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003e248 individuals randomized to receive mazdutide (3 mg, 4.5 mg, or 6 mg) or placebo.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"1374\" data-start=\"1145\"\u003e\n\u003cp class=\"\" data-end=\"1159\" data-start=\"1147\"\u003e\u003cstrong data-end=\"1158\" data-start=\"1147\"\u003eResults\u003c\/strong\u003e:\u003c\/p\u003e\n\u003cul data-end=\"1374\" data-start=\"1162\"\u003e\n\u003cli class=\"\" data-end=\"1203\" data-start=\"1162\"\u003e\n\u003cp class=\"\" data-end=\"1203\" data-start=\"1164\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003e\u003cstrong data-is-only-node=\"\" data-end=\"18\" data-start=\"0\"\u003eMazdutide 3 mg\u003c\/strong\u003e: Mean weight reduction of 6.7%.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"1247\" data-start=\"1206\"\u003e\n\u003cp class=\"\" data-end=\"1247\" data-start=\"1208\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003e\u003cstrong data-is-only-node=\"\" data-end=\"20\" data-start=\"0\"\u003eMazdutide 4.5 mg\u003c\/strong\u003e: Mean weight reduction of 10.4%.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"1291\" data-start=\"1250\"\u003e\n\u003cp class=\"\" data-end=\"1291\" data-start=\"1252\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003e\u003cstrong data-is-only-node=\"\" data-end=\"18\" data-start=\"0\"\u003eMazdutide 6 mg\u003c\/strong\u003e: Mean weight reduction of 11.3%.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"1374\" data-start=\"1294\"\u003e\n\u003cp class=\"\" data-end=\"1374\" data-start=\"1296\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003e\u003cstrong data-is-only-node=\"\" data-end=\"11\" data-start=\"0\"\u003ePlacebo\u003c\/strong\u003e: Mean weight change of +1.0%.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"\" data-end=\"1454\" data-start=\"1376\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eAll mazdutide doses were well tolerated, with gastrointestinal symptoms (e.g., nausea, diarrhea) being the most common adverse events.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"\" data-end=\"1454\" data-start=\"1376\"\u003e\u003cstrong data-end=\"1490\" data-start=\"1460\"\u003e3.2. Phase 3 GLORY-1 Study\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"\" data-end=\"1610\" data-start=\"1492\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eThe GLORY-1 Phase 3 trial assessed mazdutide's efficacy in weight management among adults with obesity or overweight.\u003c\/span\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cul data-end=\"1754\" data-start=\"1612\"\u003e\n\u003cli class=\"\" data-end=\"1754\" data-start=\"1612\"\u003e\n\u003cp class=\"\" data-end=\"1627\" data-start=\"1614\"\u003e\u003cstrong data-end=\"1626\" data-start=\"1614\"\u003eFindings\u003c\/strong\u003e:\u003c\/p\u003e\n\u003cul data-end=\"1754\" data-start=\"1630\"\u003e\n\u003cli class=\"\" data-end=\"1671\" data-start=\"1630\"\u003e\n\u003cp class=\"\" data-end=\"1671\" data-start=\"1632\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eSignificant weight loss compared to placebo.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"1754\" data-start=\"1674\"\u003e\n\u003cp class=\"\" data-end=\"1754\" data-start=\"1676\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eReduction in waist circumference and improvement in cardiometabolic risk factors.\u003c\/span\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 class=\"\" data-end=\"1791\" data-start=\"1756\"\u003e\u003cstrong data-end=\"1791\" data-start=\"1760\"\u003e3.3. Phase 3 DREAMS-2 Study\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"\" data-end=\"1911\" data-start=\"1793\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eIn the DREAMS-2 Phase 3 trial, mazdutide was compared to dulaglutide in Chinese patients with T2DM.\u003c\/span\u003e \u003c\/p\u003e\n\u003cul data-end=\"2011\" data-start=\"1913\"\u003e\n\u003cli class=\"\" data-end=\"2011\" data-start=\"1913\"\u003e\n\u003cp class=\"\" data-end=\"1928\" data-start=\"1915\"\u003e\u003cstrong data-end=\"1927\" data-start=\"1915\"\u003eOutcomes\u003c\/strong\u003e:\u003c\/p\u003e\n\u003cul data-end=\"2011\" data-start=\"1931\"\u003e\n\u003cli class=\"\" data-end=\"2011\" data-start=\"1931\"\u003e\n\u003cp class=\"\" data-end=\"2011\" data-start=\"1933\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eMazdutide demonstrated superior glycemic control and greater weight reduction compared to dulaglutide.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"\" data-end=\"2016\" data-start=\"2013\"\u003e\n\u003ch2 class=\"\" data-end=\"2051\" data-start=\"2018\"\u003e\u003cstrong data-end=\"2051\" data-start=\"2021\"\u003e4. Safety and Tolerability\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"2131\" data-start=\"2053\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eAcross clinical trials, mazdutide has exhibited a favorable safety profile:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul data-end=\"2459\" data-start=\"2133\"\u003e\n\u003cli class=\"\" data-end=\"2240\" data-start=\"2133\"\u003e\n\u003cp class=\"\" data-end=\"2240\" data-start=\"2135\"\u003e\u003cstrong data-end=\"2160\" data-start=\"2135\"\u003eCommon Adverse Events\u003c\/strong\u003e: \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eGastrointestinal symptoms such as nausea and diarrhea, generally mild to moderate in severity.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2350\" data-start=\"2242\"\u003e\n\u003cp class=\"\" data-end=\"2350\" data-start=\"2244\"\u003e\u003cstrong data-end=\"2270\" data-start=\"2244\"\u003eSerious Adverse Events\u003c\/strong\u003e: \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eNo significant increase in serious adverse events compared to placebo.\u003c\/span\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003ca class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[0.5625em] font-medium text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! transition-colors duration-150 ease-in-out\" rel=\"noopener\" href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10911117\/?utm_source=chatgpt.com\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between absolute\"\u003e\u003cspan class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2459\" data-start=\"2352\"\u003e\n\u003cp class=\"\" data-end=\"2459\" data-start=\"2354\"\u003e\u003cstrong data-end=\"2379\" data-start=\"2354\"\u003eCardiovascular Safety\u003c\/strong\u003e: \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eNo notable adverse effects on heart rate or blood pressure.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"\" data-end=\"2464\" data-start=\"2461\"\u003e\n\u003ch2 class=\"\" data-end=\"2492\" data-start=\"2466\"\u003e\u003cstrong data-end=\"2492\" data-start=\"2469\"\u003e5. Pharmacokinetics\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cul data-end=\"2795\" data-start=\"2494\"\u003e\n\u003cli class=\"\" data-end=\"2594\" data-start=\"2494\"\u003e\n\u003cp class=\"\" data-end=\"2594\" data-start=\"2496\"\u003e\u003cstrong data-end=\"2514\" data-start=\"2496\"\u003eAdministration\u003c\/strong\u003e: \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eSubcutaneous injection once weekly.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2693\" data-start=\"2596\"\u003e\n\u003cp class=\"\" data-end=\"2693\" data-start=\"2598\"\u003e\u003cstrong data-end=\"2611\" data-start=\"2598\"\u003eHalf-life\u003c\/strong\u003e: \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eExtended half-life supporting weekly dosing.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2795\" data-start=\"2695\"\u003e\n\u003cp class=\"\" data-end=\"2795\" data-start=\"2697\"\u003e\u003cstrong data-end=\"2711\" data-start=\"2697\"\u003eMetabolism\u003c\/strong\u003e: \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003ePrimarily degraded by proteolytic enzymes; minimal renal excretion.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"\" data-end=\"2800\" data-start=\"2797\"\u003e\n\u003ch2 class=\"\" data-end=\"2851\" data-start=\"2802\"\u003e\u003cstrong data-end=\"2851\" data-start=\"2805\"\u003e6. Regulatory Status and Future Directions\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"3019\" data-start=\"2853\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eMazdutide is currently undergoing Phase 3 clinical trials for obesity and T2DM.\u003c\/span\u003e \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003ePending successful outcomes, regulatory submissions are anticipated in the near future.\u003c\/span\u003e \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eIts dual receptor activity positions it as a potential alternative to existing GLP-1R agonists, with the added benefit of enhanced weight loss through increased energy expenditure.\u003c\/span\u003e\u003c\/p\u003e\n\u003chr class=\"\" data-end=\"3024\" data-start=\"3021\"\u003e\n\u003ch2 class=\"\" data-end=\"3046\" data-start=\"3026\"\u003e\u003cstrong data-end=\"3046\" data-start=\"3029\"\u003e7. Conclusion\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"3214\" data-start=\"3048\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eMazdutide represents a novel therapeutic approach targeting both GLP-1 and glucagon receptors to address obesity and T2DM.\u003c\/span\u003e \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eClinical trials have demonstrated its efficacy in weight reduction and glycemic control, with a tolerable safety profile.\u003c\/span\u003e \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eOngoing Phase 3 studies will further elucidate its potential role in the management of metabolic disorders.\u003c\/span\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003ca class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[0.5625em] font-medium text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! transition-colors duration-150 ease-in-out\" rel=\"noopener\" href=\"https:\/\/www.biospace.com\/drug-development\/innovents-lilly-partnered-type-2-diabetes-drug-aces-phase-iii-in-china-inches-closer-to-approval?utm_source=chatgpt.com\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between absolute\"\u003e\u003cspan class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr class=\"\" data-end=\"3219\" data-start=\"3216\"\u003e\n\u003cp class=\"\" data-end=\"3236\" data-start=\"3221\"\u003e\u003cstrong data-end=\"3235\" data-start=\"3221\"\u003eReferences\u003c\/strong\u003e:\u003c\/p\u003e\n\u003col data-end=\"3623\" data-start=\"3238\"\u003e\n\u003cli class=\"\" data-end=\"3365\" data-start=\"3238\"\u003e\n\u003cp class=\"\" data-end=\"3365\" data-start=\"3241\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eSafety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) in Chinese adults with overweight or obesity: a randomised, double-blind, placebo-controlled, phase 2 trial. \u003cem data-end=\"217\" data-start=\"194\"\u003eNature Communications\u003c\/em\u003e.\u003c\/span\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003ca class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[0.5625em] font-medium text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! transition-colors duration-150 ease-in-out\" rel=\"noopener\" href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10719339\/?utm_source=chatgpt.com\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between absolute\"\u003e\u003cspan class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"3494\" data-start=\"3367\"\u003e\n\u003cp class=\"\" data-end=\"3494\" data-start=\"3370\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eInnovent Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA's 84th Scientific Sessions. \u003cem data-end=\"144\" data-start=\"131\"\u003ePR Newswire\u003c\/em\u003e.\u003c\/span\u003e \u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"3623\" data-start=\"3496\"\u003e\n\u003cp class=\"\" data-end=\"3623\" data-start=\"3499\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eInnovent's Phase 3 Clinical Trial DREAMS-2 of Mazdutide in Chinese Patients with Type 2 Diabetes Were Orally Presented at EASD 2024. \u003cem data-end=\"146\" data-start=\"133\"\u003ePR Newswire\u003c\/em\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684859900242,"sku":null,"price":80.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/mazdutide_10mg.png?v=1770834901"},{"product_id":"cagrilintide-10mg","title":"Cagrilintide 10mg vial","description":"\u003ch3\u003e\n\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN \u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eCONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003cp class=\"\" data-end=\"866\" data-start=\"288\"\u003e\u003cstrong data-end=\"304\" data-start=\"288\"\u003eCagrilintide\u003c\/strong\u003e is a novel, long-acting amylin analogue under development primarily for \u003cstrong data-end=\"399\" data-start=\"377\"\u003eobesity management\u003c\/strong\u003e and \u003cstrong data-end=\"439\" data-start=\"404\"\u003etype 2 diabetes mellitus (T2DM)\u003c\/strong\u003e. It mimics and extends the physiological effects of endogenous amylin—a pancreatic hormone co-secreted with insulin—by regulating \u003cstrong data-end=\"616\" data-start=\"570\"\u003egastric emptying, satiety, and food intake\u003c\/strong\u003e. Cagrilintide is administered \u003cstrong data-end=\"662\" data-start=\"647\"\u003eonce weekly\u003c\/strong\u003e via subcutaneous injection and is being investigated both as \u003cstrong data-end=\"739\" data-start=\"724\"\u003emonotherapy\u003c\/strong\u003e and in \u003cstrong data-end=\"779\" data-start=\"747\"\u003ecombination with semaglutide\u003c\/strong\u003e, a GLP-1 receptor agonist, in a dual-agonist formulation referred to as \u003cstrong data-end=\"865\" data-start=\"852\"\u003eCagriSema\u003c\/strong\u003e.\u003c\/p\u003e\n\u003chr class=\"\" data-end=\"871\" data-start=\"868\"\u003e\n\u003ch2 class=\"\" data-end=\"902\" data-start=\"873\"\u003e\u003cstrong data-end=\"902\" data-start=\"876\"\u003e2. Mechanism of Action\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"983\" data-start=\"904\"\u003eCagrilintide exerts its pharmacologic effects through dual receptor activation:\u003c\/p\u003e\n\u003cul data-end=\"1213\" data-start=\"985\"\u003e\n\u003cli class=\"\" data-end=\"1103\" data-start=\"985\"\u003e\n\u003cp class=\"\" data-end=\"1103\" data-start=\"987\"\u003e\u003cstrong data-end=\"1015\" data-start=\"987\"\u003eAmylin Receptor Agonism:\u003c\/strong\u003e Enhances satiety, delays gastric emptying, and reduces postprandial glucagon secretion.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"1213\" data-start=\"1104\"\u003e\n\u003cp class=\"\" data-end=\"1213\" data-start=\"1106\"\u003e\u003cstrong data-end=\"1155\" data-start=\"1106\"\u003eCalcitonin Receptor Agonism (minor activity):\u003c\/strong\u003e Contributes to appetite regulation and weight modulation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"\" data-end=\"1411\" data-start=\"1215\"\u003eThis dual activity distinguishes cagrilintide from endogenous amylin and its predecessor, \u003cstrong data-end=\"1320\" data-start=\"1305\"\u003epramlintide\u003c\/strong\u003e, by offering \u003cstrong data-end=\"1367\" data-start=\"1334\"\u003eprolonged receptor engagement\u003c\/strong\u003e and \u003cstrong data-end=\"1410\" data-start=\"1372\"\u003egreater weight-reduction potential\u003c\/strong\u003e.\u003c\/p\u003e\n\u003chr class=\"\" data-end=\"1416\" data-start=\"1413\"\u003e\n\u003ch2 class=\"\" data-end=\"1445\" data-start=\"1418\"\u003e\u003cstrong data-end=\"1445\" data-start=\"1421\"\u003e3. Clinical Efficacy\u003c\/strong\u003e\u003c\/h2\u003e\n\u003ch3 class=\"\" data-end=\"1478\" data-start=\"1447\"\u003e\u003cstrong data-end=\"1478\" data-start=\"1451\"\u003e3.1. Monotherapy Trials\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"\" data-end=\"1710\" data-start=\"1480\"\u003eIn a \u003cstrong data-end=\"1533\" data-start=\"1485\"\u003ePhase 2 randomized, placebo-controlled trial\u003c\/strong\u003e (Marre et al., \u003cem data-end=\"1561\" data-start=\"1549\"\u003eThe Lancet\u003c\/em\u003e, 2021), over 300 adults with obesity received varying doses of cagrilintide (0.3–4.5 mg) or liraglutide 3.0 mg daily for 26 weeks. Results included:\u003c\/p\u003e\n\u003cul data-end=\"1962\" data-start=\"1712\"\u003e\n\u003cli class=\"\" data-end=\"1791\" data-start=\"1712\"\u003e\n\u003cp class=\"\" data-end=\"1791\" data-start=\"1714\"\u003e\u003cstrong data-end=\"1739\" data-start=\"1714\"\u003eMean weight reduction\u003c\/strong\u003e of up to \u003cstrong data-end=\"1757\" data-start=\"1749\"\u003e8.1%\u003c\/strong\u003e at the highest cagrilintide dose.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"1860\" data-start=\"1792\"\u003e\n\u003cp class=\"\" data-end=\"1860\" data-start=\"1794\"\u003eSuperior weight loss versus liraglutide (6.8%) and placebo (1.6%).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"1962\" data-start=\"1861\"\u003e\n\u003cp class=\"\" data-end=\"1962\" data-start=\"1863\"\u003eImprovements in waist circumference, systolic blood pressure, and patient-reported appetite scores.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 class=\"\" data-end=\"2008\" data-start=\"1964\"\u003e\u003cstrong data-end=\"2008\" data-start=\"1968\"\u003e3.2. Combination Therapy (CagriSema)\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"\" data-end=\"2083\" data-start=\"2010\"\u003eCagrilintide has shown remarkable synergy when combined with semaglutide:\u003c\/p\u003e\n\u003ch4 class=\"\" data-end=\"2159\" data-start=\"2085\"\u003e\u003cstrong data-end=\"2159\" data-start=\"2090\"\u003ePhase 2 Trial (CagriSema vs. Semaglutide vs. Cagrilintide Alone):\u003c\/strong\u003e\u003c\/h4\u003e\n\u003cul data-end=\"2378\" data-start=\"2161\"\u003e\n\u003cli class=\"\" data-end=\"2222\" data-start=\"2161\"\u003e\n\u003cp class=\"\" data-end=\"2222\" data-start=\"2163\"\u003ePopulation: Adults with \u003cstrong data-end=\"2221\" data-start=\"2187\"\u003eT2DM and overweight or obesity\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2244\" data-start=\"2223\"\u003e\n\u003cp class=\"\" data-end=\"2244\" data-start=\"2225\"\u003eDuration: 32 weeks.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2378\" data-start=\"2245\"\u003e\n\u003cp class=\"\" data-end=\"2256\" data-start=\"2247\"\u003eFindings:\u003c\/p\u003e\n\u003cul data-end=\"2378\" data-start=\"2259\"\u003e\n\u003cli class=\"\" data-end=\"2295\" data-start=\"2259\"\u003e\n\u003cp class=\"\" data-end=\"2295\" data-start=\"2261\"\u003e\u003cstrong data-end=\"2275\" data-start=\"2261\"\u003eCagriSema:\u003c\/strong\u003e ~15.6% weight loss.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2336\" data-start=\"2298\"\u003e\n\u003cp class=\"\" data-end=\"2336\" data-start=\"2300\"\u003e\u003cstrong data-end=\"2329\" data-start=\"2300\"\u003eSemaglutide 2.4 mg alone:\u003c\/strong\u003e ~5.1%.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2378\" data-start=\"2339\"\u003e\n\u003cp class=\"\" data-end=\"2378\" data-start=\"2341\"\u003e\u003cstrong data-end=\"2371\" data-start=\"2341\"\u003eCagrilintide 2.4 mg alone:\u003c\/strong\u003e ~8.1%.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"\" data-end=\"2477\" data-start=\"2380\"\u003eThis indicates an additive or possibly synergistic effect when both agents are used concurrently.\u003c\/p\u003e\n\u003ch4 class=\"\" data-end=\"2534\" data-start=\"2479\"\u003e\u003cstrong data-end=\"2534\" data-start=\"2484\"\u003eREDEFINE 2 Phase 3 Trial (2024, Novo Nordisk):\u003c\/strong\u003e\u003c\/h4\u003e\n\u003cul data-end=\"2771\" data-start=\"2536\"\u003e\n\u003cli class=\"\" data-end=\"2585\" data-start=\"2536\"\u003e\n\u003cp class=\"\" data-end=\"2585\" data-start=\"2538\"\u003ePopulation: Adults with T2DM and BMI ≥27 kg\/m².\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2607\" data-start=\"2586\"\u003e\n\u003cp class=\"\" data-end=\"2607\" data-start=\"2588\"\u003eDuration: 68 weeks.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2771\" data-start=\"2608\"\u003e\n\u003cp class=\"\" data-end=\"2618\" data-start=\"2610\"\u003eResults:\u003c\/p\u003e\n\u003cul data-end=\"2771\" data-start=\"2621\"\u003e\n\u003cli class=\"\" data-end=\"2667\" data-start=\"2621\"\u003e\n\u003cp class=\"\" data-end=\"2667\" data-start=\"2623\"\u003e\u003cstrong data-end=\"2643\" data-start=\"2623\"\u003eCagriSema group:\u003c\/strong\u003e 15.7% mean weight loss.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2696\" data-start=\"2670\"\u003e\n\u003cp class=\"\" data-end=\"2696\" data-start=\"2672\"\u003e\u003cstrong data-end=\"2690\" data-start=\"2672\"\u003ePlacebo group:\u003c\/strong\u003e 3.1%.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2771\" data-start=\"2699\"\u003e\n\u003cp class=\"\" data-end=\"2771\" data-start=\"2701\"\u003eAlso noted improvements in HbA1c, fasting glucose, and lipid profiles.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"\" data-end=\"2776\" data-start=\"2773\"\u003e\n\u003ch2 class=\"\" data-end=\"2811\" data-start=\"2778\"\u003e\u003cstrong data-end=\"2811\" data-start=\"2781\"\u003e4. Safety and Tolerability\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"2886\" data-start=\"2813\"\u003eAcross studies, cagrilintide has demonstrated a favorable safety profile:\u003c\/p\u003e\n\u003cul data-end=\"3302\" data-start=\"2888\"\u003e\n\u003cli class=\"\" data-end=\"3011\" data-start=\"2888\"\u003e\n\u003cp class=\"\" data-end=\"3011\" data-start=\"2890\"\u003e\u003cstrong data-end=\"2921\" data-start=\"2890\"\u003eMost common adverse events:\u003c\/strong\u003e Gastrointestinal symptoms (nausea, vomiting, constipation), dose-dependent and transient.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"3096\" data-start=\"3012\"\u003e\n\u003cp class=\"\" data-end=\"3096\" data-start=\"3014\"\u003e\u003cstrong data-end=\"3036\" data-start=\"3014\"\u003eHypoglycemia risk:\u003c\/strong\u003e Minimal when used without insulin or insulin secretagogues.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"3209\" data-start=\"3097\"\u003e\n\u003cp class=\"\" data-end=\"3209\" data-start=\"3099\"\u003e\u003cstrong data-end=\"3118\" data-start=\"3099\"\u003eCardiac safety:\u003c\/strong\u003e No significant QT prolongation; no increase in major adverse cardiovascular events (MACE).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"3302\" data-start=\"3210\"\u003e\n\u003cp class=\"\" data-end=\"3302\" data-start=\"3212\"\u003e\u003cstrong data-end=\"3231\" data-start=\"3212\"\u003eImmunogenicity:\u003c\/strong\u003e Low incidence of anti-drug antibodies; no impact on efficacy observed.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"\" data-end=\"3307\" data-start=\"3304\"\u003e\n\u003ch2 class=\"\" data-end=\"3335\" data-start=\"3309\"\u003e\u003cstrong data-end=\"3335\" data-start=\"3312\"\u003e5. Pharmacokinetics\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cul data-end=\"3604\" data-start=\"3337\"\u003e\n\u003cli class=\"\" data-end=\"3409\" data-start=\"3337\"\u003e\n\u003cp class=\"\" data-end=\"3409\" data-start=\"3339\"\u003e\u003cstrong data-end=\"3353\" data-start=\"3339\"\u003eHalf-life:\u003c\/strong\u003e Approximately 150 hours, supporting once-weekly dosing.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"3495\" data-start=\"3410\"\u003e\n\u003cp class=\"\" data-end=\"3495\" data-start=\"3412\"\u003e\u003cstrong data-end=\"3427\" data-start=\"3412\"\u003eAbsorption:\u003c\/strong\u003e Delayed Tmax (~72 hours), with stable weekly plasma concentrations.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"3604\" data-start=\"3496\"\u003e\n\u003cp class=\"\" data-end=\"3604\" data-start=\"3498\"\u003e\u003cstrong data-end=\"3514\" data-start=\"3498\"\u003eElimination:\u003c\/strong\u003e Renal excretion is minor; no dose adjustment required for mild\/moderate renal impairment.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"\" data-end=\"3609\" data-start=\"3606\"\u003e\n\u003ch2 class=\"\" data-end=\"3660\" data-start=\"3611\"\u003e\u003cstrong data-end=\"3660\" data-start=\"3614\"\u003e6. Clinical Development and Future Outlook\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"3786\" data-start=\"3662\"\u003eCagrilintide is part of Novo Nordisk’s \u003cstrong data-end=\"3736\" data-start=\"3701\"\u003eREDEFINE clinical trial program\u003c\/strong\u003e, targeting both monotherapy and dual-therapy use:\u003c\/p\u003e\n\u003cul data-end=\"4152\" data-start=\"3788\"\u003e\n\u003cli class=\"\" data-end=\"3897\" data-start=\"3788\"\u003e\n\u003cp class=\"\" data-end=\"3897\" data-start=\"3790\"\u003e\u003cstrong data-end=\"3814\" data-start=\"3790\"\u003eREDEFINE 1–6 Trials:\u003c\/strong\u003e Ongoing Phase 3 studies in various patient subgroups (obesity, T2DM, prediabetes).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"4027\" data-start=\"3898\"\u003e\n\u003cp class=\"\" data-end=\"4027\" data-start=\"3900\"\u003e\u003cstrong data-end=\"3922\" data-start=\"3900\"\u003eCombination Focus:\u003c\/strong\u003e CagriSema is expected to be a \u003cstrong data-end=\"3984\" data-start=\"3953\"\u003efirst-in-class dual peptide\u003c\/strong\u003e for chronic weight and glucose management.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"4152\" data-start=\"4028\"\u003e\n\u003cp class=\"\" data-end=\"4152\" data-start=\"4030\"\u003e\u003cstrong data-end=\"4056\" data-start=\"4030\"\u003ePotential indications:\u003c\/strong\u003e Obesity, T2DM, metabolic syndrome, possibly for cardiovascular risk reduction pending outcomes.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"\" data-end=\"4299\" data-start=\"4154\"\u003eIf regulatory approval is granted, \u003cstrong data-end=\"4241\" data-start=\"4189\"\u003eCagriSema could redefine obesity pharmacotherapy\u003c\/strong\u003e, offering superior efficacy with manageable tolerability.\u003c\/p\u003e\n\u003chr class=\"\" data-end=\"4304\" data-start=\"4301\"\u003e\n\u003ch2 class=\"\" data-end=\"4326\" data-start=\"4306\"\u003e\u003cstrong data-end=\"4326\" data-start=\"4309\"\u003e7. Conclusion\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"4702\" data-start=\"4328\"\u003eCagrilintide represents a significant advancement in metabolic therapeutics. Its ability to induce meaningful weight loss, especially in combination with GLP-1 agonists like semaglutide, places it at the forefront of next-generation obesity and diabetes management. Pending long-term safety and cardiovascular outcome data, it holds promise for widespread clinical adoption.\u003c\/p\u003e\n\u003chr class=\"\" data-end=\"4707\" data-start=\"4704\"\u003e\n\u003ch2 class=\"\" data-end=\"4730\" data-start=\"4709\"\u003e\u003cstrong data-end=\"4730\" data-start=\"4712\"\u003eKey References\u003c\/strong\u003e\u003c\/h2\u003e\n\u003col data-end=\"5111\" data-start=\"4732\"\u003e\n\u003cli class=\"\" data-end=\"4807\" data-start=\"4732\"\u003e\n\u003cp class=\"\" data-end=\"4807\" data-start=\"4735\"\u003eMarre M, et al. \u003cem data-end=\"4763\" data-start=\"4751\"\u003eThe Lancet\u003c\/em\u003e, 2021. DOI: 10.1016\/S2213-8587(21)00203-0\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"4881\" data-start=\"4808\"\u003e\n\u003cp class=\"\" data-end=\"4881\" data-start=\"4811\"\u003eDavies M, et al. \u003cem data-end=\"4857\" data-start=\"4828\"\u003eLancet Diabetes Endocrinol.\u003c\/em\u003e, 2023. PMID: 37364590\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"4960\" data-start=\"4882\"\u003e\n\u003cp class=\"\" data-end=\"4960\" data-start=\"4885\"\u003eRosenstock J, et al. \u003cem data-end=\"4928\" data-start=\"4906\"\u003eDiabetes Obes Metab.\u003c\/em\u003e, 2023. DOI: 10.1111\/dom.15951\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"5024\" data-start=\"4961\"\u003e\n\u003cp class=\"\" data-end=\"5024\" data-start=\"4964\"\u003eNovo Nordisk press release: REDEFINE 2 Trial Results, 2024\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"5111\" data-start=\"5025\"\u003e\n\u003cp class=\"\" data-end=\"5111\" data-start=\"5028\"\u003eWadden TA, et al. \u003cem data-end=\"5055\" data-start=\"5046\"\u003eObesity\u003c\/em\u003e, 2024. Clinical implications of CagriSema dual therapy.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684860260690,"sku":null,"price":80.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/cagrilintide_10mg.png?v=1770834903"},{"product_id":"retratrutide-5mg-vial","title":"Retatrutide 10mg vial","description":"\u003cp style=\"text-align: center;\"\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eNOT FOR HUMAN CONSUMPTION\u003cmeta charset=\"UTF-8\"\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"616\" data-start=\"57\"\u003e\u003cstrong\u003eRetatrutide \u003c\/strong\u003eis a once-weekly, acylated \u003cstrong data-end=\"155\" data-start=\"129\"\u003etriple-agonist peptide\u003c\/strong\u003e that activates \u003cstrong data-end=\"209\" data-start=\"171\"\u003eGLP-1, GIP, and glucagon receptors\u003c\/strong\u003e. The GLP-1\/GIP components drive \u003cstrong data-end=\"310\" data-start=\"242\"\u003eappetite suppression, insulinotropic effects, and β-cell support\u003c\/strong\u003e, while the \u003cstrong data-end=\"334\" data-start=\"322\"\u003eglucagon\u003c\/strong\u003ecomponent adds \u003cstrong data-end=\"390\" data-start=\"350\"\u003eenergy-expenditure and fat-oxidation\u003c\/strong\u003e signals and may improve \u003cstrong data-end=\"436\" data-start=\"415\"\u003ehepatic steatosis\u003c\/strong\u003e. In early–mid-stage trials, the tri-agonist profile has produced \u003cstrong data-end=\"556\" data-start=\"502\"\u003eexceptional weight loss and metabolic improvements\u003c\/strong\u003e. Retatrutide is \u003cstrong data-end=\"592\" data-start=\"573\"\u003einvestigational\u003c\/strong\u003e (not FDA\/EMA-approved).\u003c\/p\u003e\n\u003chr data-end=\"621\" data-start=\"618\"\u003e\n\u003ch3 data-end=\"685\" data-start=\"623\"\u003eAdditional Benefits of Retatrutide Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"2863\" data-start=\"687\"\u003e\n\u003cthead data-end=\"715\" data-start=\"687\"\u003e\n\u003ctr data-end=\"715\" data-start=\"687\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"697\" data-start=\"687\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-col-size=\"xl\" data-end=\"715\" data-start=\"697\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"2863\" data-start=\"726\"\u003e\n\u003ctr data-end=\"999\" data-start=\"726\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"760\" data-start=\"726\"\u003e\u003cstrong data-end=\"759\" data-start=\"728\"\u003e1 Unprecedented weight loss\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"999\" data-start=\"760\"\u003ePhase 2 obesity cohorts reported \u003cstrong data-end=\"845\" data-start=\"795\"\u003e~20–25% mean body-weight reduction at 48 weeks\u003c\/strong\u003e on higher doses, with curves still trending down—exceeding typical GLP-1 and even dual GIP\/GLP-1 results. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;New England Journal of Medicine\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1247\" data-start=\"1000\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1033\" data-start=\"1000\"\u003e\u003cstrong data-end=\"1032\" data-start=\"1002\"\u003e2 Potent glycaemic control\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1247\" data-start=\"1033\"\u003eIn type 2 diabetes, \u003cstrong data-end=\"1089\" data-start=\"1055\"\u003eA1c reductions approaching ~2%\u003c\/strong\u003e with parallel fasting-glucose and post-prandial improvements; many participants reach \u003cstrong data-end=\"1187\" data-start=\"1176\"\u003eA1c \u0026lt;7%\u003c\/strong\u003e without rescue therapy. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;JCEM; Diabetes Care\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1512\" data-start=\"1248\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1281\" data-start=\"1248\"\u003e\u003cstrong data-end=\"1280\" data-start=\"1250\"\u003e3 Liver-fat \u0026amp; MASH signals\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1512\" data-start=\"1281\"\u003eMarked \u003cstrong data-end=\"1312\" data-start=\"1290\"\u003eMRI-PDFF decreases\u003c\/strong\u003e and \u003cstrong data-end=\"1341\" data-start=\"1317\"\u003eALT\/AST improvements\u003c\/strong\u003e suggest meaningful \u003cstrong data-end=\"1375\" data-start=\"1361\"\u003eNAFLD\/MASH\u003c\/strong\u003eactivity, consistent with glucagon-mediated hepatic lipid mobilization plus weight loss. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Hepatology; Liver International\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1759\" data-start=\"1513\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1550\" data-start=\"1513\"\u003e\u003cstrong data-end=\"1549\" data-start=\"1515\"\u003e4 Cardiometabolic risk profile\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1759\" data-start=\"1550\"\u003e\n\u003cstrong data-end=\"1594\" data-start=\"1552\"\u003eTriglycerides fall, HDL rises modestly\u003c\/strong\u003e, and \u003cstrong data-end=\"1627\" data-start=\"1600\"\u003enon-HDL\/apoB trend down\u003c\/strong\u003e; \u003cstrong data-end=\"1647\" data-start=\"1629\"\u003eblood pressure\u003c\/strong\u003e often drops \u003cstrong data-end=\"1678\" data-start=\"1660\"\u003e~6–10\/3–5 mmHg\u003c\/strong\u003e with waist-circumference shrinkage. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Circulation; Atherosclerosis\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2029\" data-start=\"1760\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1794\" data-start=\"1760\"\u003e\u003cstrong data-end=\"1793\" data-start=\"1762\"\u003e5 Higher energy expenditure\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2029\" data-start=\"1794\"\u003eHuman calorimetry and preclinical data show \u003cstrong data-end=\"1872\" data-start=\"1840\"\u003e↑ resting energy expenditure\u003c\/strong\u003e and \u003cstrong data-end=\"1894\" data-start=\"1877\"\u003efat oxidation\u003c\/strong\u003e, attributed to glucagon receptor activation—countering adaptive metabolic slowdown. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Cell Metabolism; Nature Metabolism\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2219\" data-start=\"2030\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2053\" data-start=\"2030\"\u003e\u003cstrong data-end=\"2052\" data-start=\"2032\"\u003e6 OSA \u0026amp; mobility\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2219\" data-start=\"2053\"\u003eLarge weight loss translates to \u003cstrong data-end=\"2117\" data-start=\"2087\"\u003eimproved AHI (sleep apnea)\u003c\/strong\u003e and \u003cstrong data-end=\"2157\" data-start=\"2122\"\u003ebetter functional capacity\/pain\u003c\/strong\u003emarkers in obesity substudies. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Chest; Obesity\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2472\" data-start=\"2220\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2265\" data-start=\"2220\"\u003e\u003cstrong data-end=\"2264\" data-start=\"2222\"\u003e7 Early β-cell\/insulin-sparing effects\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2472\" data-start=\"2265\"\u003e\n\u003cstrong data-end=\"2288\" data-start=\"2267\"\u003eGIP\/GLP-1 synergy\u003c\/strong\u003e improves \u003cstrong data-end=\"2321\" data-start=\"2298\"\u003efirst-phase insulin\u003c\/strong\u003e and \u003cstrong data-end=\"2355\" data-start=\"2326\"\u003eglucose-dependent control\u003c\/strong\u003e, allowing \u003cstrong data-end=\"2388\" data-start=\"2366\"\u003ede-intensification\u003c\/strong\u003e of other diabetes meds in some participants. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Diabetes; Diabetologia\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2674\" data-start=\"2473\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2520\" data-start=\"2473\"\u003e\u003cstrong data-end=\"2519\" data-start=\"2475\"\u003e8 Visceral-fat and ectopic-fat reduction\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2674\" data-start=\"2520\"\u003eImaging (DXA\/MRI) indicates \u003cstrong data-end=\"2599\" data-start=\"2550\"\u003epreferential loss of visceral and hepatic fat\u003c\/strong\u003e, key for cardiometabolic risk modification. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;JCM; Radiology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2863\" data-start=\"2675\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2699\" data-start=\"2675\"\u003e\u003cstrong data-end=\"2698\" data-start=\"2677\"\u003e9 Quality of life\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2863\" data-start=\"2699\"\u003eMeaningful improvements in \u003cstrong data-end=\"2778\" data-start=\"2728\"\u003esatiety, cravings, physical function, and PROs\u003c\/strong\u003e accompany weight\/metabolic change. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Obesity; Quality of Life Research\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"2868\" data-start=\"2865\"\u003e\n\u003ch2 data-end=\"2905\" data-start=\"2870\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-end=\"2942\" data-start=\"2907\"\u003e2.1 Receptor Pharmacodynamics\u003c\/h3\u003e\n\u003cul data-end=\"3389\" data-start=\"2943\"\u003e\n\u003cli data-end=\"3047\" data-start=\"2943\"\u003e\n\u003cp data-end=\"3047\" data-start=\"2945\"\u003e\u003cstrong data-end=\"2956\" data-start=\"2945\"\u003eGLP-1R:\u003c\/strong\u003e ↓ appetite, ↓ gastric emptying, ↑ glucose-dependent insulin, ↓ glucagon (post-prandial).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3170\" data-start=\"3048\"\u003e\n\u003cp data-end=\"3170\" data-start=\"3050\"\u003e\u003cstrong data-end=\"3059\" data-start=\"3050\"\u003eGIPR:\u003c\/strong\u003e Amplifies insulin secretion, may enhance \u003cstrong data-end=\"3136\" data-start=\"3101\"\u003eadipocyte metabolic flexibility\u003c\/strong\u003e and GI tolerability with GLP-1.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3389\" data-start=\"3171\"\u003e\n\u003cp data-end=\"3389\" data-start=\"3173\"\u003e\u003cstrong data-end=\"3193\" data-start=\"3173\"\u003eGCGR (glucagon):\u003c\/strong\u003e ↑ energy expenditure and fat oxidation; \u003cstrong data-end=\"3264\" data-start=\"3234\"\u003ehepatic lipid mobilization\u003c\/strong\u003e and \u003cstrong data-end=\"3287\" data-start=\"3269\"\u003eanti-steatotic\u003c\/strong\u003e effects; modest ↑ hepatic glucose output that is \u003cstrong data-end=\"3357\" data-start=\"3337\"\u003ecounter-balanced\u003c\/strong\u003e by GLP-1\/GIP glycaemic control.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-end=\"3418\" data-start=\"3391\"\u003e2.2 Down-stream Biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"3891\" data-start=\"3420\"\u003e\n\u003cthead data-end=\"3462\" data-start=\"3420\"\u003e\n\u003ctr data-end=\"3462\" data-start=\"3420\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3430\" data-start=\"3420\"\u003ePathway\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"3451\" data-start=\"3430\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3462\" data-start=\"3451\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"3891\" data-start=\"3477\"\u003e\n\u003ctr data-end=\"3557\" data-start=\"3477\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3508\" data-start=\"3477\"\u003e\u003cstrong data-end=\"3507\" data-start=\"3479\"\u003ePOMC\/AgRP (hypothalamus)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3532\" data-start=\"3508\"\u003eSatiety ↑, cravings ↓\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3557\" data-start=\"3532\"\u003eCNS appetite circuits\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3641\" data-start=\"3558\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3582\" data-start=\"3558\"\u003e\u003cstrong data-end=\"3581\" data-start=\"3560\"\u003eIslet (GLP-1\/GIP)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3629\" data-start=\"3582\"\u003eGlucose-dependent insulin ↑, β-cell stress ↓\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3641\" data-start=\"3629\"\u003ePancreas\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3724\" data-start=\"3642\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3678\" data-start=\"3642\"\u003e\u003cstrong data-end=\"3677\" data-start=\"3644\"\u003eHepatic lipid handling (GCGR)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3715\" data-start=\"3678\"\u003eTG export\/oxidation ↑, steatosis ↓\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3724\" data-start=\"3715\"\u003eLiver\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3800\" data-start=\"3725\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3751\" data-start=\"3725\"\u003e\u003cstrong data-end=\"3750\" data-start=\"3727\"\u003eBrown\/white adipose\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3782\" data-start=\"3751\"\u003eThermogenesis\/FAO programs ↑\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3800\" data-start=\"3782\"\u003eAdipose tissue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3891\" data-start=\"3801\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3816\" data-start=\"3801\"\u003e\u003cstrong data-end=\"3815\" data-start=\"3803\"\u003eCV-renal\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3873\" data-start=\"3816\"\u003eBP ↓, natriuresis signals ↑ (weight-mediated + direct)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3891\" data-start=\"3873\"\u003eVascular\/renal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"3896\" data-start=\"3893\"\u003e\n\u003ch2 data-end=\"3920\" data-start=\"3898\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cul data-end=\"4330\" data-start=\"3922\"\u003e\n\u003cli data-end=\"4014\" data-start=\"3922\"\u003e\n\u003cp data-end=\"4014\" data-start=\"3924\"\u003e\u003cstrong data-end=\"3934\" data-start=\"3924\"\u003eRoute:\u003c\/strong\u003e \u003cstrong data-end=\"3963\" data-start=\"3935\"\u003eOnce-weekly SC injection\u003c\/strong\u003e with dose-escalation to improve GI tolerability.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4119\" data-start=\"4015\"\u003e\n\u003cp data-end=\"4119\" data-start=\"4017\"\u003e\u003cstrong data-end=\"4042\" data-start=\"4017\"\u003eAbsorption\/half-life:\u003c\/strong\u003e Engineered for \u003cstrong data-end=\"4091\" data-start=\"4058\"\u003emulti-day half-life (~1 week)\u003c\/strong\u003e supporting weekly dosing.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4267\" data-start=\"4120\"\u003e\n\u003cp data-end=\"4267\" data-start=\"4122\"\u003e\u003cstrong data-end=\"4149\" data-start=\"4122\"\u003eDistribution\/clearance:\u003c\/strong\u003e Albumin-binding\/acylation prolong exposure; peptide catabolism via proteases; renal\/hepatic clearance of fragments.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4330\" data-start=\"4268\"\u003e\n\u003cp data-end=\"4330\" data-start=\"4270\"\u003e\u003cstrong data-end=\"4292\" data-start=\"4270\"\u003eFood interactions:\u003c\/strong\u003e Not clinically relevant (injected).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"4335\" data-start=\"4332\"\u003e\n\u003ch2 data-end=\"4377\" data-start=\"4337\"\u003e4. Pre-clinical and Clinical Evidence\u003c\/h2\u003e\n\u003ch3 data-end=\"4415\" data-start=\"4379\"\u003e4.1 Obesity (without diabetes)\u003c\/h3\u003e\n\u003cp data-end=\"4637\" data-start=\"4416\"\u003eDose-ranging Phase 2 showed \u003cstrong data-end=\"4481\" data-start=\"4444\"\u003elarge, dose-dependent weight loss\u003c\/strong\u003e through 48 weeks, with a majority of participants achieving \u003cstrong data-end=\"4550\" data-start=\"4542\"\u003e≥15%\u003c\/strong\u003e and many \u003cstrong data-end=\"4568\" data-start=\"4560\"\u003e≥20%\u003c\/strong\u003e loss. Trajectories suggested additional loss with continued therapy.\u003c\/p\u003e\n\u003ch3 data-end=\"4664\" data-start=\"4639\"\u003e4.2 Type 2 Diabetes\u003c\/h3\u003e\n\u003cp data-end=\"4899\" data-start=\"4665\"\u003eRetatrutide produced \u003cstrong data-end=\"4722\" data-start=\"4686\"\u003erobust A1c and weight reductions\u003c\/strong\u003e vs placebo\/active comparators, improving fasting\/post-prandial glucose, time-in-range (CGM), lipids, and BP. Hypoglycaemia was \u003cstrong data-end=\"4862\" data-start=\"4850\"\u003euncommon\u003c\/strong\u003e outside insulin\/sulfonylurea co-use.\u003c\/p\u003e\n\u003ch3 data-end=\"4921\" data-start=\"4901\"\u003e4.3 NAFLD\/MASH\u003c\/h3\u003e\n\u003cp data-end=\"5101\" data-start=\"4922\"\u003eMeaningful \u003cstrong data-end=\"4956\" data-start=\"4933\"\u003eMRI-PDFF reductions\u003c\/strong\u003e and enzyme improvements occurred early, consistent with \u003cstrong data-end=\"5060\" data-start=\"5013\"\u003edual weight-dependent and glucagon-mediated\u003c\/strong\u003e effects; histology programs are ongoing.\u003c\/p\u003e\n\u003cblockquote data-end=\"5339\" data-start=\"5103\"\u003e\n\u003cp data-end=\"5339\" data-start=\"5105\"\u003e\u003cstrong data-end=\"5131\" data-start=\"5105\"\u003eEvidence quality note:\u003c\/strong\u003e Data to date are \u003cstrong data-end=\"5160\" data-start=\"5149\"\u003ePhase 2\u003c\/strong\u003e (plus expanding Phase 3 programs). Magnitudes above are representative of published results; long-term outcomes (CV events, MASH histology, hard renal endpoints) are \u003cstrong data-end=\"5338\" data-start=\"5327\"\u003epending\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003chr data-end=\"5344\" data-start=\"5341\"\u003e\n\u003ch2 data-end=\"5379\" data-start=\"5346\"\u003e5. Emerging Clinical Interests\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"5879\" data-start=\"5381\"\u003e\n\u003cthead data-end=\"5411\" data-start=\"5381\"\u003e\n\u003ctr data-end=\"5411\" data-start=\"5381\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5389\" data-start=\"5381\"\u003eField\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"5401\" data-start=\"5389\"\u003eRationale\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5411\" data-start=\"5401\"\u003eStatus\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"5879\" data-start=\"5426\"\u003e\n\u003ctr data-end=\"5503\" data-start=\"5426\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5459\" data-start=\"5426\"\u003e\u003cstrong data-end=\"5458\" data-start=\"5428\"\u003eObesity (broad BMI ranges)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5492\" data-start=\"5459\"\u003eSuperior weight loss potential\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5503\" data-start=\"5492\"\u003ePhase 3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5584\" data-start=\"5504\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5541\" data-start=\"5504\"\u003e\u003cstrong data-end=\"5540\" data-start=\"5506\"\u003eT2D (mono\/combination therapy)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5571\" data-start=\"5541\"\u003eStrong A1c + weight effects\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5584\" data-start=\"5571\"\u003ePhase 2→3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5654\" data-start=\"5585\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5602\" data-start=\"5585\"\u003e\u003cstrong data-end=\"5601\" data-start=\"5587\"\u003eMASH\/NAFLD\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5636\" data-start=\"5602\"\u003eLiver-fat and fibrosis pathways\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5654\" data-start=\"5636\"\u003eOngoing trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5712\" data-start=\"5655\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5665\" data-start=\"5655\"\u003e\u003cstrong data-end=\"5664\" data-start=\"5657\"\u003eOSA\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5697\" data-start=\"5665\"\u003eWeight-linked AHI improvement\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5712\" data-start=\"5697\"\u003eExploratory\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5786\" data-start=\"5713\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5738\" data-start=\"5713\"\u003e\u003cstrong data-end=\"5737\" data-start=\"5715\"\u003eHFpEF with obesity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5775\" data-start=\"5738\"\u003eWeight\/BP\/VO₂ \u0026amp; congestion signals\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5786\" data-start=\"5775\"\u003eConcept\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5879\" data-start=\"5787\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5817\" data-start=\"5787\"\u003e\u003cstrong data-end=\"5816\" data-start=\"5789\"\u003ePCOS\/metabolic syndrome\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5864\" data-start=\"5817\"\u003eWeight, insulin resistance, ovulatory milieu\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5879\" data-start=\"5864\"\u003eExploratory\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"5884\" data-start=\"5881\"\u003e\n\u003ch2 data-end=\"5915\" data-start=\"5886\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cul data-end=\"7000\" data-start=\"5917\"\u003e\n\u003cli data-end=\"6108\" data-start=\"5917\"\u003e\n\u003cp data-end=\"6108\" data-start=\"5919\"\u003e\u003cstrong data-end=\"5962\" data-start=\"5919\"\u003eCommon (dose-related, typically early):\u003c\/strong\u003e \u003cstrong data-end=\"6022\" data-start=\"5963\"\u003eNausea, vomiting, diarrhea\/constipation, abdominal pain\u003c\/strong\u003e, \u003cstrong data-end=\"6056\" data-start=\"6024\"\u003etransient decreased appetite\u003c\/strong\u003e; generally manageable with \u003cstrong data-end=\"6105\" data-start=\"6084\"\u003egradual titration\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6234\" data-start=\"6109\"\u003e\n\u003cp data-end=\"6234\" data-start=\"6111\"\u003e\u003cstrong data-end=\"6127\" data-start=\"6111\"\u003eVitals\/labs:\u003c\/strong\u003e \u003cstrong data-end=\"6150\" data-start=\"6128\"\u003eModest HR increase\u003c\/strong\u003e (few bpm); \u003cstrong data-end=\"6178\" data-start=\"6162\"\u003eBP decreases\u003c\/strong\u003e; \u003cstrong data-end=\"6191\" data-start=\"6180\"\u003eALT\/AST\u003c\/strong\u003e usually fall with weight\/liver-fat loss.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6343\" data-start=\"6235\"\u003e\n\u003cp data-end=\"6343\" data-start=\"6237\"\u003e\u003cstrong data-end=\"6253\" data-start=\"6237\"\u003eGallbladder:\u003c\/strong\u003e Risk of \u003cstrong data-end=\"6294\" data-start=\"6262\"\u003echolelithiasis\/cholecystitis\u003c\/strong\u003e rises with rapid weight loss—monitor symptoms.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6430\" data-start=\"6344\"\u003e\n\u003cp data-end=\"6430\" data-start=\"6346\"\u003e\u003cstrong data-end=\"6359\" data-start=\"6346\"\u003ePancreas:\u003c\/strong\u003e \u003cstrong data-end=\"6376\" data-start=\"6360\"\u003ePancreatitis\u003c\/strong\u003e is rare; counsel on symptoms and stop if suspected.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6544\" data-start=\"6431\"\u003e\n\u003cp data-end=\"6544\" data-start=\"6433\"\u003e\u003cstrong data-end=\"6449\" data-start=\"6433\"\u003eGI motility:\u003c\/strong\u003e \u003cstrong data-end=\"6483\" data-start=\"6450\"\u003eGastroparesis\/aspiration risk\u003c\/strong\u003e around anesthesia—follow peri-procedural fasting guidance.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6659\" data-start=\"6545\"\u003e\n\u003cp data-end=\"6659\" data-start=\"6547\"\u003e\u003cstrong data-end=\"6565\" data-start=\"6547\"\u003eHypoglycaemia:\u003c\/strong\u003e Uncommon without insulin\/secretagogues; adjust those doses as weight and glycaemia improve.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6848\" data-start=\"6660\"\u003e\n\u003cp data-end=\"6848\" data-start=\"6662\"\u003e\u003cstrong data-end=\"6704\" data-start=\"6662\"\u003eThyroid C-cell warning (class\/rodent):\u003c\/strong\u003e GLP-1–based agents carry a \u003cstrong data-end=\"6762\" data-start=\"6732\"\u003erodent C-cell tumor signal\u003c\/strong\u003e; \u003cstrong data-end=\"6817\" data-start=\"6764\"\u003eavoid with personal\/family history of MTC or MEN2\u003c\/strong\u003e pending specific label data.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7000\" data-start=\"6849\"\u003e\n\u003cp data-end=\"7000\" data-start=\"6851\"\u003e\u003cstrong data-end=\"6881\" data-start=\"6851\"\u003eContraindications\/caution:\u003c\/strong\u003e Pregnancy\/breastfeeding, severe GI disease, active gallbladder disease, pancreatitis history—use specialist judgement.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"7031\" data-start=\"7002\"\u003e\u003cstrong data-end=\"7031\" data-start=\"7002\"\u003eComparative safety matrix\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"7609\" data-start=\"7033\"\u003e\n\u003cthead data-end=\"7135\" data-start=\"7033\"\u003e\n\u003ctr data-end=\"7135\" data-start=\"7033\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"7043\" data-start=\"7033\"\u003eFeature\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"7078\" data-start=\"7043\"\u003e\u003cstrong data-end=\"7077\" data-start=\"7045\"\u003eRetatrutide (GLP-1\/GIP\/GCGR)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"7108\" data-start=\"7078\"\u003e\u003cstrong data-end=\"7107\" data-start=\"7080\"\u003eTirzepatide (GLP-1\/GIP)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"7135\" data-start=\"7108\"\u003e\u003cstrong data-end=\"7133\" data-start=\"7110\"\u003eSemaglutide (GLP-1)\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"7609\" data-start=\"7154\"\u003e\n\u003ctr data-end=\"7274\" data-start=\"7154\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7180\" data-start=\"7154\"\u003eWeight loss (48–72 wks)\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7231\" data-start=\"7180\"\u003e\n\u003cstrong data-end=\"7195\" data-start=\"7182\"\u003eVery high\u003c\/strong\u003e (≥20% avg at upper doses, Phase 2)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7252\" data-start=\"7231\"\u003e\n\u003cstrong data-end=\"7241\" data-start=\"7233\"\u003eHigh\u003c\/strong\u003e (≈15–22%)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7274\" data-start=\"7252\"\u003e\n\u003cstrong data-end=\"7262\" data-start=\"7254\"\u003eHigh\u003c\/strong\u003e (≈12–17%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7335\" data-start=\"7275\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7290\" data-start=\"7275\"\u003eA1c lowering\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7306\" data-start=\"7290\"\u003e\n\u003cstrong data-end=\"7299\" data-start=\"7292\"\u003e~2%\u003c\/strong\u003e (T2D)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7320\" data-start=\"7306\"\u003e\u003cstrong data-end=\"7319\" data-start=\"7308\"\u003e~2–2.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7335\" data-start=\"7320\"\u003e\u003cstrong data-end=\"7333\" data-start=\"7322\"\u003e~1.5–2%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7402\" data-start=\"7336\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7357\" data-start=\"7336\"\u003eEnergy expenditure\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7376\" data-start=\"7357\"\u003e\u003cstrong data-end=\"7375\" data-start=\"7359\"\u003e↑ (glucagon)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7391\" data-start=\"7376\"\u003eNeutral–mild\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7402\" data-start=\"7391\"\u003eNeutral\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7502\" data-start=\"7403\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7421\" data-start=\"7403\"\u003eGI tolerability\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7449\" data-start=\"7421\"\u003eGLP-1-like; titration key\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7487\" data-start=\"7449\"\u003eGLP-1-like; improved vs GLP-1 alone\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7502\" data-start=\"7487\"\u003eGLP-1-class\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7555\" data-start=\"7503\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7511\" data-start=\"7503\"\u003eHR\/BP\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7534\" data-start=\"7511\"\u003eHR ↑ small; \u003cstrong data-end=\"7533\" data-start=\"7525\"\u003eBP ↓\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7544\" data-start=\"7534\"\u003eSimilar\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7555\" data-start=\"7544\"\u003eSimilar\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7609\" data-start=\"7556\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7569\" data-start=\"7556\"\u003eNAFLD\/MASH\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7590\" data-start=\"7569\"\u003e\u003cstrong data-end=\"7589\" data-start=\"7571\"\u003eStrong signals\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7599\" data-start=\"7590\"\u003eStrong\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7609\" data-start=\"7599\"\u003eStrong\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"7614\" data-start=\"7611\"\u003e\n\u003ch2 data-end=\"7642\" data-start=\"7616\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-end=\"7946\" data-start=\"7644\"\u003e\n\u003cli data-end=\"7725\" data-start=\"7644\"\u003e\n\u003cp data-end=\"7725\" data-start=\"7646\"\u003e\u003cstrong data-end=\"7666\" data-start=\"7646\"\u003eApproval status:\u003c\/strong\u003e \u003cstrong data-end=\"7686\" data-start=\"7667\"\u003eInvestigational\u003c\/strong\u003e; \u003cstrong data-end=\"7718\" data-start=\"7688\"\u003eno marketing authorization\u003c\/strong\u003e yet.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7834\" data-start=\"7726\"\u003e\n\u003cp data-end=\"7834\" data-start=\"7728\"\u003e\u003cstrong data-end=\"7741\" data-start=\"7728\"\u003ePrograms:\u003c\/strong\u003e Late-phase \u003cstrong data-end=\"7777\" data-start=\"7753\"\u003eobesity and diabetes\u003c\/strong\u003e trials underway; \u003cstrong data-end=\"7812\" data-start=\"7795\"\u003eliver-disease\u003c\/strong\u003e programs expanding.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7946\" data-start=\"7835\"\u003e\n\u003cp data-end=\"7946\" data-start=\"7837\"\u003e\u003cstrong data-end=\"7860\" data-start=\"7837\"\u003eUse outside trials:\u003c\/strong\u003e Not recommended; compounded “tri-agonists” are \u003cstrong data-end=\"7915\" data-start=\"7908\"\u003enot\u003c\/strong\u003e equivalent to GMP retatrutide.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"7951\" data-start=\"7948\"\u003e\n\u003ch2 data-end=\"7976\" data-start=\"7953\"\u003e8. Future Directions\u003c\/h2\u003e\n\u003cul data-end=\"8580\" data-start=\"7978\"\u003e\n\u003cli data-end=\"8075\" data-start=\"7978\"\u003e\n\u003cp data-end=\"8075\" data-start=\"7980\"\u003e\u003cstrong data-end=\"8020\" data-start=\"7980\"\u003eCardiovascular-outcomes trial (CVOT)\u003c\/strong\u003e to quantify \u003cstrong data-end=\"8051\" data-start=\"8033\"\u003eMACE reduction\u003c\/strong\u003e and renal protection.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8150\" data-start=\"8076\"\u003e\n\u003cp data-end=\"8150\" data-start=\"8078\"\u003e\u003cstrong data-end=\"8109\" data-start=\"8078\"\u003eHistology-based MASH trials\u003c\/strong\u003e (NASH resolution, fibrosis endpoints).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8261\" data-start=\"8151\"\u003e\n\u003cp data-end=\"8261\" data-start=\"8153\"\u003e\u003cstrong data-end=\"8184\" data-start=\"8153\"\u003eBody-composition \u0026amp; function\u003c\/strong\u003e: DXA\/MRI (visceral\/ectopic fat, lean-mass preservation), \u003cstrong data-end=\"8258\" data-start=\"8242\"\u003estrength\/VO₂\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8354\" data-start=\"8262\"\u003e\n\u003cp data-end=\"8354\" data-start=\"8264\"\u003e\u003cstrong data-end=\"8298\" data-start=\"8264\"\u003eDose-finding\/titration science\u003c\/strong\u003e to balance maximal efficacy with \u003cstrong data-end=\"8351\" data-start=\"8332\"\u003eGI tolerability\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8491\" data-start=\"8355\"\u003e\n\u003cp data-end=\"8491\" data-start=\"8357\"\u003e\u003cstrong data-end=\"8383\" data-start=\"8357\"\u003eCombination strategies\u003c\/strong\u003e (e.g., \u003cstrong data-end=\"8402\" data-start=\"8391\"\u003estatins\u003c\/strong\u003e, \u003cstrong data-end=\"8424\" data-start=\"8404\"\u003eSGLT2 inhibitors\u003c\/strong\u003e) and \u003cstrong data-end=\"8449\" data-start=\"8430\"\u003eperi-procedural\u003c\/strong\u003e protocols (aspiration risk mitigation).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8580\" data-start=\"8492\"\u003e\n\u003cp data-end=\"8580\" data-start=\"8494\"\u003e\u003cstrong data-end=\"8523\" data-start=\"8494\"\u003ePatient-reported outcomes\u003c\/strong\u003e on satiety, cravings, and QoL to guide shared decisions.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"8585\" data-start=\"8582\"\u003e\n\u003ch3 data-end=\"8610\" data-start=\"8587\"\u003eSelected References\u003c\/h3\u003e\n\u003cul data-end=\"9272\" data-start=\"8612\"\u003e\n\u003cli data-end=\"8733\" data-start=\"8612\"\u003e\n\u003cp data-end=\"8733\" data-start=\"8614\"\u003e\u003cstrong data-end=\"8649\" data-start=\"8614\"\u003eNew England Journal of Medicine\u003c\/strong\u003e — Phase 2 retatrutide in obesity: magnitude of weight loss and metabolic effects.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8840\" data-start=\"8734\"\u003e\n\u003cp data-end=\"8840\" data-start=\"8736\"\u003e\u003cstrong data-end=\"8759\" data-start=\"8736\"\u003eDiabetes Care; JCEM\u003c\/strong\u003e — Glycaemic efficacy and β-cell physiology with incretin\/glucagon tri-agonism.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8940\" data-start=\"8841\"\u003e\n\u003cp data-end=\"8940\" data-start=\"8843\"\u003e\u003cstrong data-end=\"8878\" data-start=\"8843\"\u003eHepatology; Liver International\u003c\/strong\u003e — Incretin\/glucagon pathways in hepatic steatosis and MASH.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9055\" data-start=\"8941\"\u003e\n\u003cp data-end=\"9055\" data-start=\"8943\"\u003e\u003cstrong data-end=\"8981\" data-start=\"8943\"\u003eCell Metabolism; Nature Metabolism\u003c\/strong\u003e — Mechanistic work on tri-agonists (energy expenditure, fat oxidation).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9150\" data-start=\"9056\"\u003e\n\u003cp data-end=\"9150\" data-start=\"9058\"\u003e\u003cstrong data-end=\"9090\" data-start=\"9058\"\u003eCirculation; Atherosclerosis\u003c\/strong\u003e — Cardiometabolic risk-factor changes (BP, lipids, apoB).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9272\" data-start=\"9151\"\u003e\n\u003cp data-end=\"9272\" data-start=\"9153\"\u003e\u003cstrong data-end=\"9197\" data-start=\"9153\"\u003eObesity; Quality of Life Research; Chest\u003c\/strong\u003e — PROs, functional outcomes, and OSA signals with substantial weight loss\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":52684871270738,"sku":"10","price":65.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/retatrutide.png?v=1770834975"}],"url":"https:\/\/sciencepeptideslab.com\/collections\/glp-1.oembed","provider":"Science Peptides Lab","version":"1.0","type":"link"}